[go: up one dir, main page]

WO2025008476A2 - Procédé d'immobilisation de protéines - Google Patents

Procédé d'immobilisation de protéines Download PDF

Info

Publication number
WO2025008476A2
WO2025008476A2 PCT/EP2024/068917 EP2024068917W WO2025008476A2 WO 2025008476 A2 WO2025008476 A2 WO 2025008476A2 EP 2024068917 W EP2024068917 W EP 2024068917W WO 2025008476 A2 WO2025008476 A2 WO 2025008476A2
Authority
WO
WIPO (PCT)
Prior art keywords
fragment
solid carrier
protein
protective layer
immobilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/068917
Other languages
English (en)
Other versions
WO2025008476A3 (fr
Inventor
Vanessa KRONENBERG
Gabriele SPECIOSO
Manon BRIAND
Emilie LAPRÉVOTTE
Yves Victor René DUDAL
Patrick Shahgaldian
John Ashleigh WATSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perseo Pharma AG
Original Assignee
Perseo Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perseo Pharma AG filed Critical Perseo Pharma AG
Publication of WO2025008476A2 publication Critical patent/WO2025008476A2/fr
Publication of WO2025008476A3 publication Critical patent/WO2025008476A3/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/06—Enzymes or microbial cells immobilised on or in an organic carrier attached to the carrier via a bridging agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to a method of producing a composition, the composition comprising a solid carrier, a protein or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the protein or a fragment thereof by embedding the protein or a fragment thereof, and optionally a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group.
  • the present invention also relates to the composition obtainable by the method.
  • Proteins such as enzymes are frequently needed, e.g. in industrial applications, diagnostics or for therapeutic use.
  • a layer of protective material has been suggested in the prior art to immobilize the proteins on the surface of a carrier and to protect them with a layer of protective material.
  • Such an approach has been described e.g. in WO2015/014888 Al which discloses a biocatalytical composition comprising a solid carrier, a functional constituent like an enzyme and a protective layer for protecting the functional constituent by embedding the functional constituent at least partially and a process to produce such biocatalytical composition.
  • the method described in WO20 15/014888 Al is difficult to use in large scale as the load of protein per dry weight of particle is low.
  • the present invention provides a method of producing a composition, the composition comprising a solid carrier, a protein or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the protein or a fragment thereof by embedding the protein or a fragment thereof, and optionally a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group, the method comprising the following steps:
  • step (c) forming a protective layer on the surface of the solid carrier to protect the protein or the fragment thereof immobilized on the solid carrier, wherein the linker which has not connected the solid carrier with the protein or a fragment thereof in step (b), or a part therof, covalently binds the protective layer to the protein or the fragment thereof; and optionally
  • the present invention also provides a composition
  • a composition comprising a solid carrier, a protein or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the protein or a fragment thereof by embedding the protein or a fragment thereof, and optionally a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group, wherein the composition is obtainable by the methods described herein.
  • Figure 1 shows a schematic representation of the process for the production of the composition of the invention: a) engineered PAL or fragment thereof is immobilized on the solid carrier; b) and c) a protective layer grows around the immobilized engineered PAL or fragment thereof embedding the immobilized engineered PAL or fragment thereof; and d) a functional constituent is immobilized on the surface of the protective layer.
  • Figure 2 shows the added value of the covalent bonding of the PAL surface to the protective layer.
  • A PAL quantification performed on reaction supernatants of PAL-based silica nanoparticles NP-l(l), NP-1(2) and NP-1.
  • B PAL loading per dry weight of SNP.
  • C PAL activities of SNPs expressed in U/g SNP.
  • D PAL-specific activities expressed in U/g PAL.
  • Figure 3 shows the phenylalanine ammonia lyase (PAL) activity of the nanoparticles.
  • PAL phenylalanine ammonia lyase
  • Figure 4 shows PAL resistance to external stresses.
  • PAL-based silica nanoparticles NP-1 and engineered PAL were exposed to (A-B) acidic condition (pH4) or (C) to proteases and their stability was assessed by the measurement of the PAL enzymatic activity at different time points.
  • Figure 5 shows the in vitro biocompatibility and efficacy of PAL-based silica nanoparticles NP-1 on model of intestinal barrier.
  • A In vitro assessment of the integrity of the intestinal barrier by the measurement of the transepithelial electrical resistance (TEER). Differentiated Caco-2/HT29-MTX-E12 co-culture were exposed to PAL-based silica nanoparticles NP-1 (9.7mU) in presence or not of pancreatin (30mU) or to pancreatin (30mU) alone for 6h.
  • the graph represents the time course profile evolution of averaged normalized TEER data over 6h.
  • the dash line represents the untreated condition.
  • FIG 6) shows the quantification of trans-cinnamic acid (TCA) in urine of rats.
  • Urines were collected over a period of 24h post dosing and analysis by LC-MS.
  • Graphs show the concentration of d5- hippuric acid in the urines. **p ⁇ 0.01 by t-test.
  • FIG 7) shows the plasmatic concentration of Phe in BTBR-/W7 C "" /J mice.
  • BTBR-/W7 C "" /J mice having ad libitum access to drinking water containing L-Phe were dosed intraduodenally with PAL-based silica nanoparticles NP-1 (0.581U; 7mg), inactive nanoparticles NP-2 (7mg) or engineered PAL (0.581U) twice per day over a period of 12 days. Blood samples were taken at days 0, 4, 6,8 10 and 12 for plasma extraction and analysis by LC-MS.
  • A shows the plasmatic concentration of Phe in BTBR-/W7 C "" /J mice.
  • Figure 8 shows absorbance of nanoparticles PAL-based silica nanoparticles NP-1, NP-l(l) and NP-1 (2) at 460 nm.
  • Figure 9) shows a schematic representation of the process for the production of the composition of the invention: a) a disaccharidase or fragment thereof (indicated as “Protein”) is immobilized on the solid carrier; b) and c) a protective layer grows around the immobilized disaccharidase or fragment thereof embedding the immobilized disaccharidase or fragment thereof; and d) a functional constituent is immobilized on the surface of the protective layer.
  • a disaccharidase or fragment thereof indicated as “Protein”
  • a protective layer grows around the immobilized disaccharidase or fragment thereof embedding the immobilized disaccharidase or fragment thereof
  • a functional constituent is immobilized on the surface of the protective layer.
  • Figure 10 shows the added value of the covalent bonding of the lactase surface to the protective layer.
  • A Lactase quantification performed on reaction supernatants of lactasebased silica nanoparticles NP-2(1), NP-2(2) and NP-2.
  • B Lactase loading per dry weight of SNP.
  • Figure 11 shows the disaccharidase activity of the nanoparticles.
  • Lactase activity in U/g of lactase-based silica nanoparticles NP-2 after exposure to lactose.
  • Invertase activity in U/mg of invertase-based silica nanoparticles NP-3 after exposure to sucrose.
  • C Isomaltase activity (in U/g) of isomaltase-based silica nanoparticles NP-4 after exposure to isomaltose.
  • D Isomaltase and Invertase activity (in U/g) of invertase/isomaltase-based silica nanoparticles NP-5 after exposure to isomaltose and sucrose, respectively.
  • Figure 12 shows the in vitro biocompatibility of a representative model of nanoparticles on an intestinal barrier.
  • A In vitro assessment of the integrity of the intestinal barrier by the measurement of the transepithelial electrical resistance (TEER). Differentiated Caco-2/HT29- MTX-E12 co-culture were exposed to inactive nanoparticles NP-1 (0.5mg/mL and Img/mL) for 16h. TEER data was normalized to the control point consisting in the equilibrium value before the addition of inactive nanoparticles NP-1 (defined as control) and set at 100%. The graph represents the time course profile evolution of averaged normalized TEER data over 16h. The dash line represents the untreated condition.
  • TEER transepithelial electrical resistance
  • Figure 13 shows the differences in the size of cecum in rats.
  • Wistar rats were daily dosed intraduodenally with lactase-based silica nanoparticles NP-2, inactive silica nanoparticles NP-1, or the vehicle and immediately gavaged with lactose over a period of 15 days. At termination, the size of the cecum was evaluated.
  • A Pictures of the gastrointestinal tract in rats. The circles show the cecum.
  • C Histogram shows the cecum size in cm 3 assessed by MRI imaging. *p ⁇ 0.05, **p ⁇ 0.01 by one-way ANOVA test.
  • Figure 14 shows the in vitro digestion of sucrose on a model of intestinal barrier. Differentiated Caco-2/HT29-MTX-E12 co-culture were exposed to different amount of invertase-based silica nanoparticles NP-3 (0.5mU or ImU) in presence of sucrose for 4h at the apical side of the barrier. The hydrolysis of sucrose was evaluated by the quantification of glucose in the basal side of the barrier. The graph shows the time course profile evolution of the accumulation of glucose over 4h.
  • Figure 15 shows absorbance of nanoparticles lactase-based silica nanoparticles NP-2, NP- 2(1) and NP-2(2) at 460 nm.
  • Figure 16 shows a schematic representation of the process for the production of the composition of the invention: a) to a solid carrier, a lipase with closed lid, a protease, an amylase and an agent (displayed as round circle) which interacts with the lid domain of the lipase is provided and the lipase with an open lid, the protease and the amylase are immobilized on the solid carrier; b) and c) a protective layer grows around the immobilized lipase with an open lid, the protease and the amylase, embedding all three enzymes) and d) a functional constituent is immobilized on the surface of the protective layer.
  • A SPECT/CT images were acquired at 0.25, 3, 8 and 24 hours after intraduodenal dosing with in In-NP-l and 111 In-NP-2.
  • Graphs represent the relative quantification (in %) of nanoparticles at imaging time points for the small intestine compartment.
  • Figure 18 shows the activities of lipase and/or a fragment thereof, protease and/or a fragment thereof and amylase and/or a fragment thereof comprised by pancreatin as immobilized and protected on the nanoparticles.
  • A Lipase activity (in U/g) of pancreatin-based silica nanoparticles NP-3 after exposure to olive oil.
  • B Protease activity in (U/mg) of pancreatinbased silica nanoparticles NP-5 after exposure to casein.
  • C Amylase activity (in U/g) of pancreatin-based silica nanoparticles NP-3 after exposure to amylase substrate solution.
  • FIG 19 shows the relative quantification of plasmatic triglycerides (TG) of pancreatic duct ligated (PDL) rats.
  • Blood samples were taken before and at 0.25, 0.5, 1, 1.5, 2, 4, 6h after treatment for plasma extraction and analysis by LC-MS.
  • Graphs show the peak area of triolein (TG(54:3)).
  • Figure 20 shows the comparison of plasmatic triglycerides (TG) concentration between healthy minipigs and pancreatic duct ligated (PDL) minipigs treated with pancreatin-based silica nanoparticles NP-3.
  • Blood samples were taken before dosing and at 0.083, 0.25, 0.5, 1, 2, 3,4, and 6h after the dosing for TG analysis.
  • A Graphs show the plasmatic concentration of TG in minipigs determined with Konelab analyzer.
  • B Histograms show the area under the curves (AUC) of plasmatic concentration of TG in minipigs.
  • Figure 21 shows the fecal fat content of minipigs under high fat diet. Healthy and PDL minipigs were fed with high fat diet over a period of 25 days. PDL minipgs were dosed with pancreatin-based silica nanoparticles NP-3 twice a day for 10 days. Feces were collected at days 8, 9 and 10, and fecal homogenates were analyzed by near infrared spectroscopy for fecal fat quantification. (A) The histograms show the absolute fecal fat measurements. (B) The graph shows the normalized fecal fat homogenate fat content relative to healthy and untreated PDL minipigs.
  • Figure 22 shows the in vitro biocompatibility of pancreatin-based silica nanoparticles NP-5 on an intestinal barrier.
  • A In vitro assessment of the integrity of the intestinal barrier by the measurement of the transepithelial electrical resistance (TEER). Differentiated Caco-2/HT29- MTX-E12 co-culture were exposed to increasing amount of pancreatin-based silica nanoparticles NP-5 or pancreatin (from 32.9 to 263.6 U/m 2 ) for 20h.
  • TEER data was normalized with the equilibrium value before the addition of pancreatin-based silica nanoparticles NP-5 or pancreatin set at 100%.
  • the graph represents the time course profile evolution of averaged normalized TEER data over 20h.
  • the dash line represents the untreated condition.
  • ZO-1 zonula occludens 1
  • Figure 23 shows the added value of the covalent bonding of pancreatin surface to the protective layer.
  • A Protein quantification performed on reaction supernatants of pancreatinbased silica nanoparticles NP-3 and NP-3(1).
  • B Pancreatin loading per dry weight of SNP.
  • C Lipase activities of SNPs expressed in pmol/min.
  • D Pancreatin-specific activities expressed in U/g of pancreatin.
  • Figure 24 shows absorbance of nanoparticles pancreatin-based silica nanoparticles NP-3 and NP-3(1) at 460 nm.
  • Figure 25 shows a schematic representation of the process for the production of the composition of the invention: a) to a solid carrier, a lipase or a fragment thereof with closed lid and an agent (displayed as round circle) which interacts with the lid domain of the lipase or a fragment thereof is provided and the lipase or a fragment thereof with an open lid is immobilized on the solid carrier; b) and c) a protective layer grows around the immobilized lipase or the fragment with an open lid thereof embedding the immobilized lipase or the fragment thereof.
  • Figure 26 shows the 3D structure of pancreatic lipase in a) its inactive conformation (with closed lid) and b) active conformation (with opened lid).
  • the active site of pancreatic lipase is covered by a lid that prevents substrates from reaching the enzyme active site ( Figure 26a).
  • the opening of the lipase lid is induced by interactions with an agent which interacts with the lid domain of the lipase e.g. bile salts and/or a protein cofactor called colipase, allowing the stabilization of the active conformation of pancreatic lipase (Figure 26b).
  • Figure 27 shows the kinetics of lipase substrate hydrolysis by recombinant human pancreatic lipase (HRL) with or without colipase (CLPS): a) in its free form; b) immobilized at the surface of silica nanoparticles (SNPs) and protected in an organosilca layer made of APTES, TEOS and Benzyltriethoxysilane (ATB).
  • HRL human pancreatic lipase
  • CLPS colipase
  • Figure 28 shows the kinetics of lipase substrate hydrolysis by porcine pancreatic lipase (PL) with or without colipase (CLPS) immobilized at the surface of silica nanoparticles (SNPs) and protected in an organosilica layer made of APTES, TEOS and Benzyltriethoxysilane (ATB).
  • Figure 29 shows the kinetics of lipase substrate hydrolysis by free human recombinant lipase (HRL) using increasing concentrations of sodium taurocholate (NaTc).
  • HRL free human recombinant lipase
  • NaTc sodium taurocholate
  • Figure 30 shows the kinetics of lipase substrate hydrolysis by porcine pancreatic lipase (PL) immobilized at the surface of silica nanoparticles (SNPs) and protected in an organosilica layer made of APTES, TEOS and Benzyltriethoxysilane (ATB) with or without sodium taurocholate (NaTc).
  • PL pancreatic lipase
  • Figure 31 shows the 3D structure of pancreatic lipase activated by a colipase-mimicking peptide.
  • Figure 32 shows the added value of the covalent bonding of HRL surface to the protective layer.
  • A Protein quantification performed on reaction supernatants of HRL-based silica nanoparticles NP-1, NP-l(l), NP-1(2).
  • B HRL loading per dry weight of SNP.
  • C Lipase activities of nanoparticles expressed in U Ll ⁇ i m.n/g of SNP.
  • D HRL-specific activities expressed in U ⁇ M/mm/g of HRL.
  • Figure 33 shows absorbance of nanoparticles HRL-based silica nanoparticles NP-1, NP-l(l), NP-1 (2) at 460 nm.
  • the present invention relates to a method of producing a composition, the composition comprising a solid carrier, a protein or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the protein or a fragment thereof by embedding the protein or a fragment thereof, and optionally a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group, the method comprising the following steps:
  • step (c) forming a protective layer on the surface of the solid carrier to protect the protein or the fragment thereof immobilized on the solid carrier, wherein the linker which has not connected the solid carrier with the protein or a fragment thereof in step (b), or a part therof, covalently binds the protective layer to the protein or the fragment thereof; and optionally
  • the present invention also provides a composition
  • a composition comprising a solid carrier, a protein or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the protein or a fragment thereof by embedding the protein or a fragment thereof, and optionally a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group, wherein the composition is obtainable by the methods described herein.
  • the term "about” refers to a range of values ⁇ 10% of a specified value.
  • the phrase “about 200” includes ⁇ 10% of 200, or from 180 to 220.
  • solid carrier refers usually to a particle.
  • the solid carrier is a monodisperse particle or a poly disperse particle, more preferably a monodisperse particle.
  • the solid carrier usually comprises organic particles, inorganic particles, organic-inorganic particles, self-assembling organic particles, silica particles, gold particles, titanium particles and is preferably a silica particle, more preferably a silica nanoparticle (SNP).
  • SNP silica nanoparticle
  • the particle size of the solid carrier is usually between and 1 nm and 1000 pm, preferably between 10 nm and 100 pm, particularly about 50 nm.
  • linker or “cross-linker” which are used synonymously herein refers to any linking reagents containing groups, which are capable of binding to specific functional groups (e.g. primary amines, sulfhydryls, etc.).
  • a linker in the context of the present invention usually connects the surface of the solid carrier with the protein or a fragment thereof i.e. with the enzyme e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof .
  • a linker may be immobilized on the surface of the solid carrier e.g. on the silica surface as a carrier material and then the protein or a fragment thereof i.e.
  • the enzyme e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof may be bound to an unoccupied binding-site of the linker.
  • the linker may firstly bind to the protein or a fragment thereof i.e. the enzyme e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof and then the linker bound to the enzyme e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof may bind with its unoccupied binding-site to the solid carrier.
  • Various types of linkers are known in the art, including but not limited to straight or branched-chain carbon linkers, heterocyclic carbon linkers, peptide linkers, polyether linkers, and linkers that are known in the art as tags.
  • the term “protective layer” as used herein refers to a layer for protecting the functional properties of the protein or fragment thereof e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof immobilized on the surface of the solid carrier.
  • the protective layer of the present invention is usually built with building blocks at least part of which are monomers capable of interacting with both each other usually by covalent binding and the immobilized protein or fragment thereof e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof usually by non-covalent binding.
  • the protective layer is formed on the surface of the solid carrier to protect the protein or the fragment thereof e.g.
  • the protective layers are usually homogeneous layers where at least 50%, preferably at least 70%, more preferably at least 90% of the protein or fragment therof e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof are embedded in the protective layer.
  • protein or a fragment thereof includes naturally occurring proteins or a fragment thereof and also includes artificially engineered proteins or a fragment thereof. Artificially engineered proteins or a fragment thereof are e.g. variants or functionally active fragments of the protein.
  • fragment of a protein in relation to the protein and “functionally active fragment of a protein” are thus used synonymously herein.
  • variants or functionally active fragments thereof’ in relation to the protein of the present invention is meant that the fragment or variant (such as an analogue, derivative or mutant) is capable of exercising the same physiological function as the protein.
  • variants include naturally occurring allelic variants and non-naturally occurring variants. Additions, deletions, substitutions and derivatizations of one or more of the amino acids are contemplated so long as the modifications do not result in loss of functional activity of the fragment or variant.
  • the functionally active fragment or variant has at least about 80% sequence identity more preferably at least about 90% sequence identity, even more preferably at least about 95% sequence identity, most preferably at least about 98% sequence identity to the relevant part of the protein.
  • a fragment of a protein as defined herein does usually have the same functional properties as the protein i.e. the full length protein from which it is derived.
  • a fragment of a protein contains usually between 100 and 1000 amino acids, preferably between 150 and 500 amino acids, more preferably between 300 and 450 amino acids.
  • a preferred protein or a fragment thereof of the present invention is an enzyme or a fragment thereof, more preferred is an enzyme or fragment thereof selected from the group consisting of hydrolases and lyases, or a fragment thereof.
  • An even more more preferred protein or a fragment thereof of the present invention is selected from the group consisting of a lipase or a fragment thereof, a protease or a fragment thereof, an amylase or a fragment thereof, pancreatin or a protein or a fragment thereof comprised by pancreatin, an engineered phenylalanine ammonia lyase (PAL) or a fragment thereof, and a disaccharidase or a fragment thereof.
  • PAL phenylalanine ammonia lyase
  • lipase or a fragment thereof includes naturally occurring lipases or a fragment thereof and also includes artificially engineered lipases or a fragment thereof. Artificially engineered lipases or a fragment thereof are e.g. variants or functionally active fragments of the lipase.
  • fragment of a lipase in relation to the lipase and “functionally active fragment of a lipase” are thus used synonymously herein.
  • variants or functionally active fragments thereof’ in relation to the lipase of the present invention is meant that the fragment or variant (such as an analogue, derivative or mutant) is capable of exercising the same physiological function as the lipase.
  • Such variants include naturally occurring allelic variants and non-naturally occurring variants. Additions, deletions, substitutions and derivatizations of one or more of the amino acids are contemplated so long as the modifications do not result in loss of functional activity of the fragment or variant.
  • the functionally active fragment or variant has at least about 80% sequence identity more preferably at least about 90% sequence identity, even more preferably at least about 95% sequence identity, most preferably at least about 98% sequence identity to the relevant part of the lipase.
  • a fragment of a lipase as defined herein does usually have the same functional properties as the lipase i.e. the full length enzyme from which it is derived and includes at least the lid domain and the substrate binding region.
  • a fragment of a lipase contains usually between 100 and 450 amino acids, preferably between 150 and 400 amino acids, more preferably between 200 and 350 amino acids.
  • a preferred lipase or a fragment thereof is a lipase or a fragment thereof extracted from pancreas, more preferably extracted from pancreas of porcine origin, even more preferably a lipase or a fragment thereof comprised by pancreatin.
  • the lipase or a fragment thereof is a recombinant human pancreatic lipase (HRL) or a fragment therof or a porcine pancreatic lipase or a fragment thereof, preferably a recombinant human pancreatic lipase (HRL) or a fragment thereof, more preferably a full length recombinant human pancreatic lipase (HRL).
  • HRL recombinant human pancreatic lipase
  • HRL recombinant human pancreatic lipase
  • protease or a fragment thereof includes naturally occurring proteases or a fragment thereof and also includes artificially engineered proteases or a fragment thereof. Artificially engineered proteases or a fragment thereof are e.g. variants or functionally active fragments of the protease.
  • fragment of a protease in relation to the protease and “functionally active fragment of a protease” are thus used synonymously herein.
  • variants or functionally active fragments thereof’ in relation to the protease of the present invention is meant that the fragment or variant (such as an analogue, derivative or mutant) is capable of exercising the same physiological function as the protease.
  • variants include naturally occurring allelic variants and non-naturally occurring variants. Additions, deletions, substitutions and derivatizations of one or more of the amino acids are contemplated so long as the modifications do not result in loss of functional activity of the fragment or variant.
  • the functionally active fragment or variant has at least about 80% sequence identity more preferably at least about 90% sequence identity, even more preferably at least about 95% sequence identity, most preferably at least about 98% sequence identity to the relevant part of the protease.
  • a fragment of a protease as defined herein does usually have the same functional properties as the protease from which it is derived.
  • a fragment of a protease contains usually between 50 and 200 amino acids, preferably between 75 and 175 amino acids, more preferably between 100 and 150 amino acids.
  • a preferred protease or a fragment thereof is a protease or a fragment thereof extracted from pancreas, more preferably extracted from pancreas of porcine origin, even more preferably a protease or a fragment thereof comprised by pancreatin.
  • amylase or a fragment thereof includes naturally occurring amylases or a fragment thereof and also includes artificially engineered amylases or a fragment thereof. Artificially engineered amylases or a fragment thereof are e.g. variants or functionally active fragments of the amylase.
  • fragment of an amylase “fragment thereof’ in relation to the amylase and “functionally active fragment of an amylase” are thus used synonymously herein.
  • variants or functionally active fragments thereof’ in relation to the amylase of the present invention is meant that the fragment or variant (such as an analogue, derivative or mutant) is capable of exercising the same physiological function as the amylase.
  • Such variants include naturally occurring allelic variants and non-naturally occurring variants. Additions, deletions, substitutions and derivatizations of one or more of the amino acids are contemplated so long as the modifications do not result in loss of functional activity of the fragment or variant.
  • the functionally active fragment or variant has at least about 80% sequence identity more preferably at least about 90% sequence identity, even more preferably at least about 95% sequence identity, most preferably at least about 98% sequence identity to the relevant part of the amylase.
  • a fragment of an amylase as defined herein does usually have the same functional properties as the amylase from which it is derived.
  • a fragment of a amylase contains usually between 100 and 550 amino acids, preferably between 200 and 500 amino acids, more preferably between 300 and 450 amino acids.
  • a preferred amylase or a fragment thereof is an amylase or a fragment thereof extracted from pancreas, more preferably extracted from pancreas of porcine origin, even more preferably an amylase or a fragment thereof comprised by pancreatin.
  • pancreatin also known as and used interchangeably herein with “pancreatic enzymes” as used herein refers to pancreatic enzyme preparation derived from porcine pancreatic glands and comprises a lipase or a fragment thereof, a protease or a fragment thereof and an amylase or a fragment thereof.
  • pancreatin as used herein also comprises formulated pancreatic enzymes like capsules comprising pancreatic enzymes e.g. Zenpep ®.
  • phenylalanine ammonia lyase or a fragment thereof' or “PAL or a fragment thereof’ as used herein refers to a class of enzymes within the aromatic amino acid lyase family (EC 4.3.1.23, EC 4.3.1.24 and EC4.3.1.25) which also includes histidine ammonia lyase, and tyrosine ammonia lyase.
  • PALs are also sometimes referred to as phenylalanine/tyrosine ammonia lyases because some PALs may use tyrosine as well as phenylalanine as a substrate.
  • PAL catalyze the conversion of L- phenylalanine to transcinnamic acid and ammonia.
  • PAL activity refers to the enzymatic activity of PAL polypeptides.
  • PAL may also contain the cofactor 3,5- dihydro-5- methylidene-4H-imidazol-4-one (MIO). This cofactor maybe required for catalytic activity and is formed by cyclization and dehydration of a conserved active site Alal67-Serl68-Glyl69 tripeptide segment.
  • MIO 3,5- dihydro-5- methylidene-4H-imidazol-4-one
  • engineered and "non-naturally occurring" when used with reference to a phenylalanine ammonia lyase or a fragment thereof as used herein refers to a phenylalanine ammonia lyase or a fragment thereof corresponding to the natural or native form of the phenylalanine ammonia lyase or a fragment thereof that has been modified in a manner that would not otherwise exist in nature.
  • engineered phenylalanine ammonia lyase or a fragment thereof does not include or encompass "wild-type” and “naturally-occurring” phenylalanine ammonia lyases or fragments thereof.
  • wild-type and “naturally- occurring” refer to the form of phenylalanine ammonia lyases or fragments thereof found in nature.
  • a wild-type phenylalanine ammonia lyase or a fragments thereof is a polypeptide present in an organism that can be isolated from a source in nature and which has not been intentionally modified by human manipulation.
  • Engineered PALs or fragments thereof are e.g. variants or functionally active fragments of the engineered phenylalanine ammonia lyase.
  • fragment of the engineered phenylalanine ammonia lyase fragment of the engineered phenylalanine ammonia lyase
  • fragment thereof in relation to the engineered phenylalanine ammonia lyase
  • functionally active fragment of the engineered phenylalanine ammonia lyase are thus used synonymously herein.
  • variant or functionally active fragments thereof in relation to the engineered phenylalanine ammonia lyase of the present invention is meant that the fragment or variant (such as an analogue, derivative or mutant not existing in nature) is capable of exercising the same or improved physiological function as the wild-type phenylalanine ammonia lyase.
  • a fragment of a PAL comprises the homotetrameric enzyme wherein at least one monomer, preferably all four monomers of the homotetrameric enzyme contains usually between 100 and 550 amino acids, preferably between 200 and 500 amino acids, more preferably between 300 and 450 amino acids.
  • “Improved physiological function” or “Improved enzyme property” refers to an engineered PAL that exhibits an improvement in any enzyme property as compared to a reference PAL polypeptide, such as a wild- type PAL polypeptide.
  • Improved properties include but are not limited to such properties as increased protein expression, increased thermoactivity, increased thermostability, increased pH activity, increased stability, increased enzymatic activity, increased substrate specificity and/or affinity, increased specific activity, increased resistance to substrate and/or end-product inhibition, increased chemical stability, improved chemoselectivity, improved solvent stability, increased tolerance to acidic pH, increased tolerance to proteolytic activity (i.e., reduced sensitivity to proteolysis), reduced aggregation, increased solubility, reduced immunogenicity, and altered temperature profile.
  • Preferred engineered phenylalanine ammonia lyases or fragments thereof of the present invention are the engineered phenylalanine ammonia lyases described in WO 2018/148633 Al.
  • the engineered phenylalanine ammonia lyase or a fragement thereof comprises or consists of an amino acid sequence having at least 90%, at least 95%, at least 96%, or at least 97% sequence identity to the sequence of SEQ ID NO: 1.
  • the engineered phenylalanine ammonia lyase or a fragment thereof is SEQ ID NO: 2, 3, 4 or 5.
  • the engineered phenylalanine ammonia lyase or a fragment thereof comprises the polypeptide as shown in SEQ ID NO: 5.
  • partially embedded engineered phenylalanine ammonia lyase shall mean that the engineered phenylalanine ammonia lyase is not fully covered by the protective layer, thus, the engineered phenylalanine ammonia lyase is not fully embedded in the protective layer. In one embodiment less than 50% of the engineered phenylalanine ammonia lyase of interest are covered by the protective layer, though typically at least 70% will be covered, thus improving protection of the engineered phenylalanine ammonia lyase.
  • At least 70%, more preferably at least 80%, even more preferably at least 90%, most preferably at least 95% of the engineered phenylalanine ammonia lyase of interest is covered by the protective layer.
  • around 70% to around 95%, more preferrably around 80% to around 95%, even more preferably around 90% to around 95%, most preferably around 90% to around 95, 96, 97, 98 or 99 %of the engineered phenylalanine ammonia lyase of interest are covered by the protective layer.
  • around 70%, particularly around 80%, more particularly around 90%, most particularly around 95% of the engineered phenylalanine ammonia lyase of interest is covered by the protective layer.
  • around 70%, particularly around 80%, more particularly around 90%, most particularly around 95% of the engineered phenylalanine ammonia lyase of interest is covered by the protective layer, wherein the active site is not covered.
  • engineered phenylalanine ammonia lyase shall mean that the engineered phenylalanine ammonia lyase of interest according to the invention is fully, i.e. 100% covered by the protective layer, i.e. that also the active site is covered.
  • the engineered phenylalanine ammonia lyase or a fragment thereof according to the invention is fully, i.e. 100% covered by the protective layer, i.e. that also the active site is covered.
  • At least partially embedded engineered phenylalanine ammonia lyase shall mean that the engineered phenylalanine ammonia lyase is at least partially embedded and may be fully embedded by the protective layer.
  • at least partially embedded engineered phenylalanine ammonia lyase means that the protective layer covers from about 30% and 100% of the engineered phenylalanine ammonia lyase or a fragment therof, preferably from about 50% to about 100%, more preferably from about 80% to about 100%, even more preferably from about 90% to about 100%, most preferably from about 95% to about 100 %, wherein the active site is preferably covered.
  • disaccharidase or a fragment thereof includes naturally occurring disaccharidases or a fragment thereof and also includes artificially engineered disaccharidases or a fragment thereof.
  • Disaccharidases are glycoside hydrolases, enzymes that break down certain types of sugars called disaccharides into simpler sugars called monosaccharides. In the human body, disaccharidases are made mostly in an area of the small intestine's wall called the brush border.
  • Disaccharidases includes e.g. lactase, maltase, isomaltase, trehalase and sucrase (which is also named invertase).
  • Artificially engineered disaccharidases or a fragment thereof are e.g.
  • variants or functionally active fragments of the disaccharidase are thus used synonymously herein.
  • fragment of a disaccharidase fragment thereof in relation to a disaccharidase and “functionally active fragment of a disaccharidase” are thus used synonymously herein.
  • variants or functionally active fragments thereof’ in relation to the disaccharidase of the present invention is meant that the fragment or variant (such as an analogue, derivative or mutant) is capable of exercising the same physiological function as the disaccharidase.
  • variants include naturally occurring allelic variants and non-naturally occurring variants.
  • the functionally active fragment or variant has at least about 80% sequence identity more preferably at least about 90% sequence identity, even more preferably at least about 95% sequence identity, most preferably at least about 98% sequence identity to the relevant part of the disaccharidase.
  • a fragment of an disaccharidase as defined herein does usually have the same functional properties as the disaccharidase from which it is derived.
  • a fragment of a disaccharidase contains usually between 100 and 1000 amino acids, preferably between 300 and 800 amino acids, more preferably between 500 and 700 amino acids.
  • partially embedded disaccharidase shall mean that the disaccharidase is not fully covered by the protective layer, thus, the disaccharidase is not fully embedded in the protective layer. In one embodiment less than 50% of the disaccharidase of interest are covered by the protective layer, though typically at least 70% will be covered, thus improving protection of the disaccharidase. In a preferred embodiment, at least 70%, more preferably at least 80%, even more preferably at least 90%, most preferably at least 95% of the disaccharidase of interest is covered by the protective layer.
  • around 70% to around 95%, more preferrably around 80% to around 95%, even more preferably around 90% to around 95%, most preferably around 90% to around 95, 96, 97, 98 or 99 % of the disaccharidase of interest are covered by the protective layer.
  • around 70%, particularly around 80%, more particularly around 90%, most particularly around 95% of the disaccharidase of interest is covered by the protective layer.
  • around 70%, particularly around 80%, more particularly around 90%, most particularly around 95% of the disaccharidase of interest is covered by the protective layer, wherein the active site is not covered.
  • disaccharidase as used herein shall mean that the disaccharidase of interest according to the invention is fully, i.e. 100% covered by the protective layer, i.e. that also the active site is covered.
  • At least partially embedded disaccharidase shall mean that the disaccharidase is at least partially embedded and may be fully embedded by the protective layer.
  • at least partially embedded disaccharidase means that the protective layer covers from about 30% and 100% of the disaccharidase or a fragment therof, preferably from about 50% to about 100%, more preferably from about 80% to about 100%, even more preferably from about 90% to about 100%, most preferably from about 95% to about 100 %, wherein the active site is preferably covered.
  • partially embedded protein as used herein shall mean that the protein e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof is not fully covered by the protective layer, thus, the protein e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof is not fully embedded in the protective layer.
  • less than 50% of the protein e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof are covered by the protective layer, though typically at least 70% will be covered, thus improving protection of the protein.
  • At least 70%, more preferably at least 80%, even more preferably at least 90%, most preferably at least 95% of the protein e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof is covered by the protective layer.
  • around 70% to around 95%, more preferrably around 80% to around 95%, even more preferably around 90% to around 95%, most preferably around 90% to around 95, 96, 97, 98 or 99 % of the protein e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof are covered by the protective layer.
  • around 70%, particularly around 80%, more particularly around 90%, most particularly around 95% of the protein e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof is covered by the protective layer.
  • around 70%, particularly around 80%, more particularly around 90%, most particularly around 95% of the protein e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof is covered by the protective layer, wherein the active site is not covered.
  • the term “fully embedded protein” as used herein shall mean that the protein e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof according to the invention is fully, i.e. 100% covered by the protective layer, i.e. that also the active site is covered.
  • the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof according to the invention are fully, i.e. 100% covered by the protective layer, i.e. that also the active site is covered.
  • the term “at least partially embedded protein” as used herein shall mean that the protein e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof is at least partially embedded and may be fully embedded by the protective layer.
  • “at least partially embedded protein” means that the protective layer covers from about 30% and 100% of the protein or a fragment therof e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof, preferably from about 50% to about 100%, more preferably from about 80% to about 100%, even more preferably from about 90% to about 100%, most preferably from about 95% to about 100 %, wherein the active site is preferably covered.
  • agent which interacts with the lid domain of the lipase or a fragment thereof refers to an agent which normally binds to the lid domain of the lipase or a fragment thereof and/or to the region of the lipase or a fragment thereof surrounding the lid domain, thereby causing the lid domain to shift the lipase or a fragment thereof to the open conformation and/or to maintain the open conformation of the lipase or the fragment thereof.
  • the lid domain of lipases is normally an amphipathic structure; in the closed conformation, their hydrophilic side faces the solvent, while the hydrophobic side is directed toward the catalytic pocket (Brocca S., Secundo F., Ossola M., Alberghina L., Carrea G., Lotti M. (2003). Sequence of the lid affects activity and specificity of Candida rugosa lipase isoenzymes. Protein Sci. 12, 2312-2319. 10.1110/ps.0304003). As the lipase shifts to the open conformation, the hydrophobic face becomes exposed and contributes to the substrate-binding region.
  • the agent which interacts with the lid domain of the lipase or a fragment thereof causes the lipase or a fragment to be locked in its active conformation.
  • the lipase is normally fully activated.
  • the agent which interacts with the lid domain of the lipase or a fragment thereof so that the the lipase or a fragment thereof is in the open conformation include a colipase or a fragment thereof, a colipase-mimicking peptide, and an amphipathic molecule.
  • amphipathic molecule refers to a molecule like a chemical compound containing both polar (water-soluble) and nonpolar (not water-soluble) portions in its structure. It may also relate to a molecule like a chemical compound having both hydrophobic and hydrophilic regions. Amphipathic molecules include bile salts, phospholipids, and nonionic detergents.
  • open conformation or “open conformation of a lipase or a fragment thereof’ which are used interchangeably herein refer to the conformation of the lipase or the fragment thereof where substrates can enter the lipases’ active sites and be converted.
  • closed conformation entrance of substrates to the active site of the lipase or a fragment thereof and its conversion is limited or not possible.
  • the conformation of the lipase or fragment thereof i.e. whether the lipase is in open or closed confirmation can be determined by X-ray crystallography, enzymatic activity study, site-directed spin labeling (SDSL) methods and electron paramagnetic resonance (EPR).
  • colipase or a fragment thereof as used herein includes naturally occurring colipases or a fragment thereof and also includes artificially engineered colipases or a fragment thereof. Artificially engineered colipases or a fragment thereof are e.g. variants or functionally active fragments of the lipase.
  • variants or functionally active fragments thereof in relation to the colipase of the present invention is meant that the fragment or variant (such as an analogue, derivative or mutant) is capable of exercising the same physiological function as the colipase.
  • variants include naturally occurring allelic variants and non-naturally occurring variants.
  • the functionally active fragment or variant has at least about 80% sequence identity more preferably at least about 90% sequence identity, even more preferably at least about 95% sequence identity, most preferably at least about 98% sequence identity to the relevant part of the lipase.
  • a fragment of a colipase as defined herein does have the same functional properties as the colipase from which it is derived.
  • a preferred colipase is the colipase with Uniprot number: P02703.
  • colipase mimicking peptide refers to a peptide consisting of between 10 and 40 amino acids, allowing specific amino acid residues to be geometrically located in the right position to interact with amino acids of the pancreatic lipase structure, inducing stretching of the lipase conformation and opening of the lid, and thereby having the same functional properties as the colipase.
  • a colipase mimicking peptide which can be used in the present invention is preferably the peptide as shown in SEQ ID NO: 6.
  • bile salt refers to bile acids conjugated with taurine or glycine and include sodium taurocholate, sodium glycocholate, sodium glycodeoxycholate, sodium taurodeoxycholate, sodium glycochenodeoxycholate, and sodium taurochenodeoxycholate.
  • nonionic detergent refers to a surfactantand include tetra ethylene glycol monooctyl ether, octyl-b-D-glucopyranoside, N,N-dimethyldodecylamine-N-oxide, and b-octylglucomaltoside.
  • phospholipids refers to a class of lipids whose molecule has a hydrophilic "head” containing a phosphate group and two hydrophobic "tails” derived from fatty acids, joined by an alcohol residue (usually a glycerol molecule). Phospholipids include lecithin and lysolecithin.
  • a functional constituent in the sense of the present invention is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group.
  • the term “polymer comprising repeat units wherein each repeat unit comprises at least one amino group” as used herein refers to a polymer comprising a number of repeat units (monomers), whererin each repeat unit comprises at least one amino group.
  • a preferred polymer comprises a number of repeat units (monomers), whererin each repeat unit contains one amino group, in particular one primary amino group.
  • polymer comprising repeat units wherein each repeat unit comprises at least one thiol group refers to a polymer comprising a number of repeat units (monomers), whererin each repeat unit comprises at least one thiol group.
  • a preferred polymer comprises a number of repeat units (monomers), whererin each repeat unit contains one thiol group.
  • polycarbophil-cysteine conjugates refers to conjugates which comprise cysteine covalently attached to polycarbophil. Such conjugates can be produced as referred in e.g. Bernkop-Schnurch and Thaler, 2000, Journal of Pharmaceutical Sciences 89(7):901-9.
  • polylysine refers to a-polylysine and or s-polylysine (s-poly-L-lysine, EPL), preferably 8-polylysine.
  • a-polylysine is a synthetic polymer, which can be composed of either L-lysine or D-lysine.
  • s-polylysine s-poly-L-lysine, EPL
  • EPL is typically produced as a homopolypeptide of approximately 25-30 L-lysine residues.
  • polycysteine as used herein can be composed of either L-cysteine or D-cysteine and is preferably composed of L-cysteine and comprises preferably between 2 and 30 cysteine residues, more preferably between 2 and 5 cysteine residues.
  • polyglucosamin refers to linear amino-polysaccharides composed of D-glucosamine and N-acetyl-D-glucosamine units linked by (1-4) glycosidic bonds.
  • Polyglucosamine contains free amine (-NH2) groups and may be characterized by the proportion of N-acetyl-D-glucosamine units and D-glucosamine units, which is expressed as the degree of deacetylation (DDA) of the fully acetylated polymer chitin.
  • DDA degree of deacetylation
  • a preferred polyglucosamin of the present invention is selected from the group consisting of chitin, chitosan, polyglucosaminoglycans, chondroitin, heparin, keratan and dermatan or a derivative thereof. Most preferred is a chitosan or a derivative thereof.
  • chitosan or a derivative thereof refers to a chitosan or chitosan derivative thereof including a salt thereof which has preferably a molecular weight of 2 000 Da or more, preferably in the range 25 000 - 2 000 000 Da and more preferably about 50 000 - 350 000 Da, most preferably about 50 000 - 190 000 Da or 190 000 - 310 000 Da.
  • the term chitosan derivatives includes ester, ether or other derivatives formed by reaction of acyl or alkyl groups with the OH groups. Examples are O-alkyl ethers of chitosan, O-acyl esters of chitosan. Suitable derivatives are given e.g. in G.A.E.
  • Suitable salts of chitosan include nitrates, phosphates, sulphates, xanthates, hydrochlorides, glutamates, lactates, acetates.
  • the present invention provides a method of producing a composition, the composition comprising a solid carrier, a protein or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the protein or a fragment thereof by embedding the protein or a fragment thereof, and optionally a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group, the method comprising the following steps:
  • step (c) forming a protective layer on the surface of the solid carrier to protect the protein or the fragment thereof immobilized on the solid carrier, wherein the linker which has not connected the solid carrier with the protein or a fragment thereof in step (b), or a part therof, covalently binds the protective layer to the protein or the fragment thereof; and optionally (d) immobilizing a functional constituent on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units, wherein each repeat unit comprises at least one amino group and/or at least one thiol group.
  • the method of producing a composition comprising a solid carrier, a protein or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the protein or a fragment thereof by embedding the protein or a fragment thereof, and optionally a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group, comprises the following steps:
  • step (c) forming a protective layer on the surface of the solid carrier to protect the protein or the fragment thereof immobilized on the solid carrier, wherein the linker which has not connected the solid carrier with the protein or a fragment thereof in step (b), or a part therof, covalently binds the protective layer to the protein or the fragment thereof.
  • the present invention provides a method of producing a composition, the composition comprising a solid carrier, a protein or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the protein or a fragment thereof by embedding the protein or a fragment thereof, and optionally a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group, the method comprising the following steps:
  • step (c) forming a protective layer on the surface of the solid carrier to protect the protein or the fragment thereof immobilized on the solid carrier, wherein the linker which has not connected the solid carrier with the protein or a fragment thereof in step (b), or a part therof, covalently binds the protective layer to the protein or the fragment thereof; and optionally
  • each repeat unit comprises at least one amino group and/or at least one thiol group, with the proviso that the protein or a fragment thereof is not a lipase or a fragment thereof, a protease or a fragment thereof, an amylase or a fragment thereof, pancreatin or a protein or a fragment thereof comprised by pancreatin, an engineered phenylalanine ammonia lyase (PAL) or a fragment thereof, and a disaccharidase or a fragment thereof, preferably with the proviso that the protein or a fragment thereof is not a lipase or a fragment thereof, a protease or a fragment thereof, an amylase or a fragment thereof, pancreatin or a protein or a fragment thereof comprised by pancreatin, an engineered phenyla
  • the method of producing a composition comprising a solid carrier, a protein or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the protein or a fragment thereof by embedding the protein or a fragment thereof, and optionally a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group, comprises the following steps:
  • step (c) forming a protective layer on the surface of the solid carrier to protect the protein or the fragment thereof immobilized on the solid carrier, wherein the linker which has not connected the solid carrier with the protein or a fragment thereof in step (b), or a part thereof, covalently binds the protective layer to the protein or the fragment thereof, with the proviso that the protein or a fragment thereof is not a lipase or a fragment thereof, a protease or a fragment thereof, an amylase or a fragment thereof, pancreatin or a protein or a fragment thereof comprised by pancreatin, an engineered phenylalanine ammonia lyase (PAL) or a fragment thereof, and a disaccharidase or a fragment thereof, preferably with the proviso that the protein or a fragment thereof is not a lipase or a fragment thereof, a protease or a fragment thereof, an amylase or a fragment thereof, pancreatin or a protein or a fragment
  • the protein or fragment thereof e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof can be immobilized on the surface of the solid carrier by non-covalent binding or covalent binding.
  • Non-covalent binding includes p- p (aromatic) interactions, van der Waals interactions, H-bonding interactions, and electrostatic interactions like e.g. ionic interactions.
  • the protein or fragment thereof, e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof is immobilized on the surface of the solid carrier by covalent binding or by covalent binding via a linker.
  • a solution of a protein or a fragment thereof usually comprises the protein or a fragment thereof in a buffer solution.
  • Buffers which can be used are usually phosphate, chloride, citrate, MES, MOPS, HEPES, PIPES, ACES or mixtures thereof.
  • the soultion may additionally contain sugar alcohols or non-ionic surfactants as described herein.
  • a solution of the protein or a fragment thereof can be prepared by e.g. dissolving the protein or fragment thereof in water to reconstitute the stock buffer of the protein or a fragment thereof.
  • the solid carrier is selected from the group of organic particles, inorganic particles, organic-inorganic particles, self-assembling organic particles, silica particles, gold particles, titanium particles and is preferably a silica particle, more preferably a silica nanoparticle (SNP).
  • the particle size is usually measured by measuring the diameter of the particles and is usually between 1 nm and 1000 nm, preferably between 10 nm and 100 nm, particularly about 50 nm.
  • the solid carrier is a monodisperse particle
  • the size is usually between 1 nm and 1000 nm, preferably between 10 nm and 100 nm, particularly about 50 nm.
  • the size is usually betweenl nm and 1000 pm , preferably between 10 nm and 100 pm, particularly between 50 nm and 50 pm.
  • the composition comprises a solid carrier wherein the solid carrier comprises at least 4%, preferably at least 10%, more preferably at least 20%, even more preferably between 4% and 50%, in particular between 10% and 40%, more particular between 25% and 35 %, even more particular between 15% and 25% immobilized protein or a fragment thereof per dry weight of the solid carrier.
  • monodisperse particles or polydisperse particles preferably monodisperse particles are used as solid carrier in the present invention.
  • the monodisperse particles are spherical monodisperse particles.
  • the poly disperse particles are non-spherical polydisperse particles.
  • the solid carrier is usually provided in suspension.
  • Suspension of the solid carrier can be e.g. in water, buffer or non-ionic surfactants or mixtures thereof, preferably in mixtures of water and non-ionic surfactants.
  • Non-ionic surfactants are usually selected from the group consisting of ethoxylated sorbitan esters like PEG-40 sorbitan diisostearate, polysorbate 80 (PS80), polysorbate 20 (PS20), polysorbate 40 (PS40), polysorbate 60 (PS60); block co-polymers like poloxamer 124, poloxamer 188, poloxamer 331, poloxamer 407, fatty acids ethoxylates like PEG-5 oleate, PEG-8 stearate, polyoxyl 40 stearate, polyoxyl 15 hydroxystearate, fatty alcohol ethoxylates like steareth 40; fatty acid esters like ascorbyl palmitate, beeswax, polyglyce
  • Buffers which can be used in the method of the present invention are phosphate, piperazine-N,N'-bis(2-ethanesulfonic acid), 2 -Hydroxy-3 -morpholinopropanesulfonic acid, N,N-bis[2-hydroxyethyl]-2-aminoethanesulfonic acid), (3-(N-morpholino)propanesulfonic acid), 2-[[l,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]ethanesulfonic acid, 4-(2- hydroxy ethyl)- 1 -piperazineethanesulfonic acid), 3 -(N,N-Bis[2-hydroxyethyl]amino)-2- hydroxypropanesulfonic acid, N,N-Bis(2-hydroxyethyl)-3 -amino-2-hydroxypropanesulfonic acid, N-[Tris(hydroxymethyl)methyl]glycine, Diglycine, 4-
  • the agent which interacts with the lid domain of the lipase or a fragment thereof is added to a suspension of the solid carrier, preferably the agent which interacts with the lid domain of the lipase or a fragment thereof is added together with the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof to the suspension of the solid carrier prior to immobilization of the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof on the solid carrier.
  • the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof can be added in form of pancreatin the suspension of the solid carrier prior to immobilization of the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof on the solid carrier
  • the immobilization of the protein or a fragment thereof, e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof on the solid carrier is usually carried out by adding a solution comprising a protein or a fragment thereof, e.g. a lipase or a fragment thereof, a protease or a fragment thereof and an amylase or a fragment thereof, or pancreatin or a solution thereof, to the suspension of the solid carrier.
  • a solution comprising a protein or a fragment thereof, e.g. a lipase or a fragment thereof, a protease or a fragment thereof and an amylase or a fragment thereof, or pancreatin or a solution thereof, to the suspension of the solid carrier.
  • the immobilization of the protein or a fragment thereof e.g.
  • the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof on the solid carrier is carried out by providing a suspension of the solid carrier and providing a solution comprising protein or a fragment thereof, e.g. a lipase or a fragment thereof, a protease or a fragment thereof and a amylase or a fragment thereof, or pancreatin or a solution thereof, wherein the suspension of the solid carrier is incubated with the solution comprising protein or a fragment thereof, e.g.
  • a lipase or a fragment thereof, a protease or a fragment thereof and an amylase or a fragment thereof, or pancreatin or a solution thereof to allow the protein or a fragment thereof, e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof to bind on the surface of the solid carrier.
  • the immobilization of a protein or a fragment thereof e.g.
  • a lipase on the solid carrier, a protease or a fragment thereof and an amylase or a fragment thereof, or pancreatin or a solution thereof is carried out by providing a suspension of the solid carrier, providing a solution comprising a protein or a fragment thereof, e.g. a lipase or a fragment thereof, a protease or a fragment thereof and a amylase or a fragment thereof, or pancreatin or a solution thereof, and providing a solution of the agent which interacts with the lid domain of the lipase or a fragment thereof, wherein the suspension of the solid carrier is incubated with the solution comprising protein or a fragment thereof, e.g.
  • a lipase or a fragment thereof a protease or a fragment thereof and an amylase or a fragment thereof, or pancreatin or a solution thereof, and with the solution of the agent which interacts with the lid domain of the lipase or a fragment thereof to allow the protein or a fragment thereof, e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof to bind on the surface of the solid carrier.
  • the protein or a fragment thereof is immobilized on the solid carrier by a linker, preferably a bi-functional cross-linker, binding to the protein or a fragment thereof or to a fragment thereof and to the surface of the solid carrier, preferably a linker, preferably a bi-functional cross-linker, binding to the protein or to a fragment thereof and to the surface of the solid carrier by covalent binding.
  • a linker preferably a bi-functional cross-linker
  • the surface of the solid carrier is modified to introduce a molecule or functional chemical group as anchoring point i.e. as anchoring point for the protein or a fragment thereof e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof or for the linker connecting the protein or a fragment thereof e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof to the solid carrier.
  • said anchoring point is an amine functional chemical group or moiety.
  • an amino-modified surface of the solid carrier e.g. an amino-modified silica surface may be used as modified solid carrier.
  • Such an amino-modified surface of the solid carrier may be obtained by reacting a solid carrier having a silica surface with an amino silane, e.g. with APTES.
  • the solid carrier is a solid carrier having a silica surface with an amino-modified surface, more preferably a solid carrier obtained by reacting the solid carrier having a silica surface with an amino silane, e.g. with APTES.
  • Such a modified carrier may form an amide linkage between the protein or a fragment thereof e.g.
  • the introduced molecule or functional chemical group as anchoring point is homogeneously distributed on the surface of the solid carrier.
  • the agent which interacts with the lid domain of the lipase or a fragment thereof is selected from the group consisting of a colipase or a fragment thereof, a colipase mimicking pepide, and an amphipathic molecule.
  • the agent which interacts with the lid domain of the lipase or a fragment thereof is selected from the group consisting of a colipase or a fragment thereof, a colipase mimicking pepide, and a bile salt, more preferably selected from the group consisting of a colipase or a fragment thereof, a colipase mimicking pepide, and sodium taurocholate , even more preferably selected from the group consisting of a colipase or a fragment thereof, a colipase mimicking pepide as shown in SEQ ID NO: 6, and sodium taurocholate.
  • the agent which interacts with the lid domain of the lipase or a fragment thereof is a bile salt, in particular sodium taurocholate.
  • the agent which interacts with the lid domain of the lipase or a fragment thereof interacts specifically with the lid domain of the lipase or a fragment thereof so that the lipase or a fragment thereof shifts to and/or maintains the open conformation.
  • the protective layer has a defined thickness of about 1 to about 200 nm, usually 1 to about 100 nm, preferably about 1 to about 50nm, more preferably about 1 to about 25 nm, even more preferably about 1 to about 20 nm, in particular about 1 to about 15 nm.
  • the most preferred defined thickness is about 1 to about 10 nm.
  • the layer has a defined thickness of about 5 to about 100 nm, preferably about 5 to about 50 nm, more preferably about 5 to about 25 nm, even more preferably about 5 to about 20 nm, in particular about 5 to about 15 nm.
  • the most preferred defined thickness is about 5 to about 10 nm.
  • the protective layer is usually porous and the pore size is between 1 and 100 nm, preferably between 1 and 20 nm.
  • the protein or fragment thereof e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof is partially embedded by the protective layer.
  • the protein or a fragment thereof e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof is at least partially embedded by the protective layer.
  • the protein or a fragment thereof e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof is fully embedded by the protective layer.
  • the protective layer embeds the solid carrier and embeds the protein or a fragment thereof, e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof immobilized on the surface of the solid carrier.
  • the functional constituent immobilized on the surface of the protective layer is not embedded by the protective layer.
  • the protective layer fully embeds the solid carrier and fully embeds the protein or a fragment thereof, e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof immobilized on the surface of the solid carrier.
  • the protective layer fully embeds the solid carrier and fully embeds the protein or a fragment thereof, e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof immobilized on the surface of the solid carrier and the functional constituent immobilized on the surface of the protective layer is not embedded by the protective layer. If the protective layer fully embeds the solid carrier and fully embeds the protein or a fragment thereof, e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof immobilized on the surface of the solid carrier, the protein or a fragment thereof, e.g.
  • the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof is fully, i.e. 100% covered by the protective layer, i.e. that also the active site is covered and the solid carrier is fully, i.e. 100% covered by the protective layer.
  • the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof used in the present invention are comprised by pancreatin.
  • pancreatin is used to immobilize the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof on the surface of the solid carrier.
  • the protective layer thickness can be measured, by using a microscope such as scanning electron microscope (SEM), transmission electron microscopy (TEM), scanning probe microscopy (SPM), light scattering methods or by ellipsometry.
  • SEM scanning electron microscope
  • TEM transmission electron microscopy
  • SPM scanning probe microscopy
  • the composition of the present invention is usually produced in a reaction vessel like a reactor.
  • the formation of the protective layer is usually carried out by forming the respective protective layer by building blocks, wherein the building blocks build the protective layer in a polycondensation reaction.
  • the polycondensation can be performed in different solvents, preferably in aqueous solution. Polycondensation can be easily controlled and stopped if appropriate, allowing achievement of a defined thickness of the protective layer.
  • the choice of the building blocks, which can be used to build the protective layer may depend on the known structure of the protein e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof in order to adapt the affinity of the protective layer according to optimal and/or desired parameters.
  • TEOS tetraethylorthosilicate
  • T tetraethylorthosilicate
  • APTES APTES
  • PTES Propyltriethyoxysilane
  • IBTES Isobutyltriethoxysilane
  • HTMEOS Hydroxymethyltriethoxysilane
  • BTES Benzyltriethoxysilane
  • Ureidopropyltriethoxysilane designated as “UPTES”
  • CETES Carboxyethyltriethoxysilane
  • Structural building blocks are usually precursors of inorganic silica, capable of forming 4 covalent bonds in the layer formed.
  • Protective building blocks are usually organosilanes, bearing an organic moiety endowed with the ability to interact with the proteins e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof.
  • Preferred structural building blocks are tetravalent silanes, in particular tetra-alkoxy-silanes.
  • Preferred protective building blocks are trivalent silanes, in particular tri-alkoxy-silanes.
  • More preferred structural building blocks are mixtures of tetravalent silanes and trivalent silanes, in particular mixtures of tetra-alkoxy- silanes and tri-alkoxy-silanes. Even more preferred structural building blocks are selected from the group consisting of tetraethylorthosilicate, tetra-(2-hydroxyethyl)silane, and tetramethylorthosilicate.
  • Even more preferred protective building blocks are selected from the group consisting of carboxyethylsilanetriol, benzyl silanes, propylsilanes, isobutyl silanes, n- octylsilanes, hydroxysilanes, bis(2-hydroxyethyl)-3 -aminopropylsilanes, aminopropylsilanes, urei dopropyl sil anes, (N - Acetylgly cyl)-3 -aminopropyl silanes, hydroxy(polyethyleneoxy)propyl]triethoxysilanes, in particular selected from benzyltriethoxysilane (BTES), propyltriethoxysilane, isobutyltriethoxysilane, n- octyltriethoxysilane, hydroxymethyltriethoxysilane, bis(2-hydroxyethyl)-3 - aminopropyltri
  • Particular preferred building blocks are TEOS as structural building block and APTES, BTES, and/or HTMEOS, preferably APTES and/or BTES as protective building block.
  • TEOS as structural building block and APTES and/or BTES as protective building block are used to build the protective layer.
  • the reaction time of the building blocks with the solid carrier carrying the immobilized enzymes can depend on the length of the linker, if a linker is used, and the size of the protein e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof.
  • the reaction is usually carried out for a time period of between 0.5 to 10 hours, preferably between 1 and 5 hours, more preferably between 1 and 4 hours, even more preferably between 2 and 4 hours, preferably in aqueous solution and preferably at room temperature of about 5 to about 25 °C or at about 20 °C.
  • the formation of the protective layer can be stopped by actively stopping the polycondensation reaction e.g. by removing the non-reacted building blocks e.g. by a washing step or by self-stopping of the polycondensation reaction caused by a limited amount of buidling blocks.
  • the protein or a fragment thereof e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof is immobilized on the solid carrier by at least partly modifying the surface of the solid carrier by introducing a molecule as anchoring point as described supra for the protein or a fragment thereof e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereofand by using a linker, preferably a cross-linker binding to the anchoring point and the protein e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof.
  • a linker preferably a cross-linker binding to the anchoring point and the protein e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereof.
  • the introduced molecule as anchoring point and/or the linker are homogeneously distributed on the surface of the solid carrier.
  • Step (a) of the method is usually carried out by providing the solid carrier in suspension in water, buffer or non-ionic surfactants or mixtures thereof, preferably in suspension in water and/or non-ionic surfactants, more preferably in suspension in water and/or non-ionic surfactants wherein no buffer is present in the suspension, even more preferably in suspension in mixtures of water and non-ionic surfactants in particular in suspension in mixtures of water and non-ionic surfactants wherein no buffer is present in the suspension.
  • the immobilization of the protein or a fragment thereof on the solid carrier in step b) of the present method is usually carried out by adding a solution of the protein or a fragment thereof to the suspension of the solid carrier.
  • a linker to connect the solid carrier with the protein or a fragment thereof is added to the suspension of the solid carrier prior to adding the solution of the protein or a fragment thereof to the suspension of the solid carrier.
  • the immobilization of the protein or a fragment thereof on the solid carrier is carried out by providing a suspension of the solid carrier and adding a solution of the protein or a fragment thereof, wherein the suspension with the added solution of the protein or a fragment thereof is incubated to allow the protein to bind on the surface of the solid carrier.
  • the immobilization of the protein or a fragment thereof on the solid carrier in step b) is carried out by i) adding a linker to the suspension comprising the solid carrier provided in step (a), and ii) adding adding a solution of the protein or a fragment thereof, to the suspension comprising the solid carrier and the linker, wherein the linker connects the solid carrier with the protein or a fragment thereof, preferably wherein the suspension with the added solution of the protein or a fragment thereof is incubated to allow the protein to bind on the surface of the solid carrier.
  • a building block of the protective layer preferably a monomer of a building block of the protective layer, more preferably an organosilane, even more preferably a triethoxysilane, in particular APTES, is added to the suspension comprising the solid carrier and the linker, prior to adding the solution of the protein or a fragment thereof.
  • the surface of the solid carrier is at least partly modified to improve immobilization of the protein or a fragment thereof on the solid carrier.
  • the surface of the solid carrier is at least partly modified before the protein or a fragment thereof is immobilized.
  • the surface of the solid carrier can be at least partly modified by adding a molecule as anchoring point for the protein or a fragment thereof to the surface of the solid carrier as described supra.
  • the suspension comprising the solid carrier is usually incubated after each addition step described above to allow a reaction between e.g. the solid carrier and/or the molecule as anchoring point, the solid carrier and the linker and, the solid carrier comprising the linker and the protein or a fragment thereof, respectively, so that the protein or a fragment thereof connects to the solid carrier, preferably the surface of the solid carrier, via the linker, preferably by covalent binding, thereby immobilizing the protein or a fragment thereof on the solid carrier.
  • step (b) the protein or a fragment thereof is immobilized on the solid carrier by connecting the solid carrier with the protein or a fragment thereof via a linker, wherein the solid carrier is connected with the protein or a fragment thereof by covalent binding between the linker and the solid carrier and between the linker and the protein or a fragment thereof.
  • the linker connects the surface of the solid carrier with the protein or a fragment thereof by preferably covalent binding.
  • the linker is added to the suspension of the solid carrier in i) of step (b), in a molar excess to the protein or a fragment thereof added to the suspension comprising the solid carrier and the linker in ii) of step (b), preferably the linker is added to the suspension of the solid carrier in step (b), in a 1 fold to 1000 fold molar excess to the protein or a fragment thereof added to the suspension comprising the solid carrier and the linker in ii) of step (b), more preferably the linker is added to the suspension of the solid carrier in step (b), in a 2 fold to 300 fold molar excess to the protein or a fragment thereof added to the suspension comprising the solid carrier and the linker in ii) of step (b), even more preferably the linker is added to the suspension of the solid carrier in step (b), in a 4 fold to 250 fold molar excess to the protein or a fragment thereof added to the suspension comprising the solid carrier and the linker in ii) of step (b).
  • the linker which has not connected the solid carrier with the protein or a fragment thereof in step (b), is present during formation of a protective layer on the surface of the solid carrier in step (c).
  • the linker which has not connected the solid carrier with the protein or a fragment thereof in step (b) is not removed in step (b) or step (c) or in between step (b) and (c).
  • the linker which has not connected the solid carrier with the protein or a fragment thereof in step (b) is not removed in step (b) or step (c) or in between step (b) and (c) and the linker which has not connected the solid carrier with the protein or a fragment thereof in step (b), or a part thereof, covalently binds the protective layer to the protein or the fragment thereof in step (c).
  • the amount of the linker which has not connected the solid carrier with the protein or a fragment thereof in step (b) after addition of the protein in ii), is usually between 30% and 70%, preferably between 40% and 60 %, more preferably around 50% of the amount of linker added to the solid carrier in step (b).
  • step (a) there is no washing step between adding the linker to the the suspension of the solid carrier provided in step (a) in (i) of step (b) and adding the solution of the protein or a fragment thereof to the suspension comprising the solid carrier and the linker in ii) of step (b). In one embodiment there is no washing step between any of steps (a) to (c). In one embodiment there is no washing step between adding the linker to the suspension of the solid carrier provided in step (a) in (i) of step (b) and adding the protein or a fragment thereof to the suspension comprising the solid carrier and the linker in ii) of step (b) and there is no washing step between any of steps (a) to (c).
  • the cross-linker is selected from the group consisting of glutaraldehyde, disuccinimidyl tartrate, bis[sulfosuccinimidyl]suberate, ethylene glycolbis(sulfosuccinimidylsuccinate), dimethyl adipimidate, dimethyl pimelimidate, sulfosuccinimidyl (4-iodoacetyl) aminobenzoate, l,5-difluoro-2,4-dinitrobenzene, activated sulfhydrils, sulfhydryl-reactive 2-pyridyldithiol, BSOCOES (Bis[2- (succinimidooxycarbonyloxy)ethyl]sulfone), DSP (Dithiobis[succinimidyl]propionate]), DTSSP (3,3 '-Dithiobis[sulfosuccinimidyl]propionate]
  • cross-linker is selected from glutaraldehyde, disuccinimidyl tartrate, disuccinimidyl suberate, bisfsulfosuccinimidyl] suberate, ethylene glycolbis(sulfosuccinimidylsuccinate), dimethyl adipimidate, dimethyl pimelimidate, sulfosuccinimidyl (4-iodoacetyl) aminobenzoate, l,5-difhroro-2,4-dinitrobenzene, activated sulfhydrils (e.g.
  • suflhydryl-reactive 2-pyridyldithio and a colipase-mimicking peptide, wherein the colipase-mimicking peptide can be functionalized with a chemical group that enable covalent binding to the solid carrier surface.
  • the cross-linker is selected from the group consisting of glutaraldehyde, disuccinimidyl tartrate, bis[sulfosuccinimidyl]suberate, ethylene glycolbis(sulfosuccinimidylsuccinate), dimethyl adipimidate, dimethyl pimelimidate, sulfosuccinimidyl (4-iodoacetyl) aminobenzoate, 1,5- difluoro-2,4-dinitrobenzene, BSOCOES (Bis[2-(succinimidooxycarbonyloxy)ethyl]sulfone), DSP (Dithiobis[succinimidyl]propionate]), DTSSP (3,3 '- Dithiobis[sulfosuccinimidyl]propionate]), DTBP (Dimethyl 3,3 '-dithiobispropionimidate-2 HC1), DST (Disuccinimide),
  • said cross-linker is selected from glutaraldehyde, disuccinimidyl tartrate, disuccinimidyl suberate, bisfsulfosuccinimidyl] suberate, ethylene glycolbis(sulfosuccinimidylsuccinate), dimethyl adipimidate, dimethyl pimelimidate, sulfosuccinimidyl (4-iodoacetyl) aminobenzoate, l,5-difluoro-2,4-dinitrobenzene, activated sulfhydrils (e.g. suflhydryl-reactive 2-pyridyldithio). Most preferred is glutaraldehyde.
  • the solid carrier comprising the protein e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereofand the protective layer can be stored. Storing is usually accomplished e.g. by washing the composition formed e.g. with a buffer and storing it suspended or solved in that buffer for a desired time period.
  • the solid carrier comprising the protein e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereofand the protective layer is stored at a constant temperature between 2 to 25 °C.
  • the solid carrier comprising protein e.g.
  • the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereofand the protective layer is stored 5 to 48 hours, preferably 10 to 30 hours. More preferably the solid carrier comprising the protein e.g. the lipase or a fragment thereof, the protease or a fragment thereof and the amylase or a fragment thereofand the protective layer is stored at a constant temperature between 2 to 25 °C, preferably at room temperature for 10 to 30 hours.
  • a preferred method of the present invention is a method of producing a composition, the composition comprising a solid carrier, a protein or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the protein or the fragment thereof by embedding the protein or the fragment thereof, and optionally a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units, wherein each repeat unit comprises at least one amino group and/or at least one thiol group, the method comprising the following steps:
  • step (c) forming a protective layer on the surface of the solid carrier to protect the protein or the fragment thereof immobilized on the solid carrier, wherein the linker which has not connected the solid carrier with the protein or a fragment thereof in step (b), or a part therof, covalently binds the protective layer to protein or the fragment thereof; and optionally
  • a further preferred method of the present invention is a method of producing a composition, the composition comprising a solid carrier, a protein or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the protein or the fragment thereof by embedding the protein or the fragment thereof, and optionally a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units, wherein each repeat unit comprises at least one amino group and/or at least one thiol group, comprising the following steps:
  • step (c) forming a protective layer on the surface of the solid carrier to protect the protein or the fragment thereof immobilized on the solid carrier, wherein the linker which has not connected the solid carrier with the protein or a fragment thereof in step (b), or a part therof, covalently binds the protective layer to protein or the fragment thereof.
  • the optional functional constituent binds to mucus.
  • a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group.
  • a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group is a polymer comprising repeat units wherein each repeat unit comprises at least one thiol group.
  • a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group is selected from the group consisting of a polyglucosamin, a polymerized silane-PEG-NH2 and a polymerized silane comprising an amino group.
  • the polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group is selected from the group consisting of a polyglucosamin, a polymerized silane-PEG-NH2 and polymerized APTES.
  • the polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group is selected from the group consisting of a polyglucosamin selected from the group consisting of chitin, chitosan, polyglucosaminoglycans, chondroitin, heparin, keratan and dermatan or a derivative thereof; a polymerized silane-PEG-NH2; and a polymerized silane comprising an amino group, preferably a polymerized APTES.
  • the polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group is a polyglucosamin, preferably a polyglucosamin selected from the group consisting of chitin, chitosan, polyglucosaminoglycans, chondroitin, heparin, keratan and dermatan or a derivative thereof, more preferably a chitosan or a derivative thereof.
  • a preferred polyglucosamin of the present invention is selected from the group consisting of chitin, chitosan, polyglucosaminoglycans, chondroitin, heparin, keratan and dermatan or a derivative thereof. Most preferred is a chitosan or a derivative thereof.
  • a preferred silane-PEG- NH2 of the polymerized silane-PEG-NH2 is selected from the group consisting of silane- PEG4-NH2, silane-PEG2000-NH2, and silane-PEG5000-NH2.
  • a preferred polymerized silane comprising an amino group is selected from the group consisting of APTES, amino-butyl-TES, amino-pentyl-TES, amino-hexyl-TES, amino-heptyl-TES, and amino-octyl-TES, and is in particular APTES.
  • a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group is selected from the group consisting of a polyglucosamin, a polymerized silane-PEG-NH2, a polymerized silane comprising an amino group, a polymerized silane comprising a thiol group, a polycarbophil-cysteine conjugate, a polymerized silane-PEG-thiol and a polycysteine.
  • each repeat unit comprises at least one amino group and/or at least one thiol group is selected from the group consisting of a polyglucosamin selected from the group consisting of chitin, chitosan, polyglucosaminoglycans, chondroitin, heparin, keratan and dermatan or a derivative thereof; a polymerized silane-PEG-NH2; a polymerized silane comprising a thiol group, preferably a polymerized MPTS; a polycarbophil-cysteine conjugate; a polymerized silane-PEG-thiol; and a polycysteine.
  • a polyglucosamin selected from the group consisting of chitin, chitosan, polyglucosaminoglycans, chondroitin, heparin, keratan and dermatan or a derivative thereof
  • a polymerized silane-PEG-NH2 a polymerized silane
  • the polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group is a polyglucosamin or a polymerized silane comprising a thiol group, preferably a polyglucosamin selected from the group consisting of chitin, chitosan, polyglucosaminoglycans, chondroitin, heparin, keratan and dermatan or a derivative thereof, more preferably a chitosan or a derivative thereof or a polymerized silane comprising a thiol group, a polycarbophil-cysteine conjugate, and a polymerized silane-PEG-thiol, preferably a polymerized silane comprising a thiol group.
  • the polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group is selected from the group consisting of chitin, chitosan, polyglucosaminoglycans, chondroitin, heparin, keratin, dermatan or a derivative thereof in particular chitosan or a derivative thereof, a polymerized silane-PEG- NH2 selected from the group consisting of polymerized silane-PEG4-NH2, polymerized silane- PEG2000-NH2, polymerized silane-PEG5000-NH2, a polymerized silane comprising an amino group which is preferably polymerized APTES and a polymerized silane comprising a thiol group, which is preferably polymerized MPTS.
  • a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group is selected from the group consisting of a polyglucosamin, a polymerized silane-PEG-NH2, a polymerized silane comprising an amino group and a polymerized silane comprising a thiol group.
  • the polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group is selected from the group consisting of a polyglucosamin, a polymerized silane-PEG-NH2, polymerized APTES and polymerized MPTS.
  • the polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group is selected from the group consisting of a polyglucosamin selected from the group consisting of chitin, chitosan, polyglucosaminoglycans, chondroitin, heparin, keratan and dermatan or a derivative thereof; a polymerized silane-PEG-NH2; a polymerized silane comprising an amino group, preferably a polymerized APTES; and a polymerized silane comprising a thiol group, preferably polymerized MPTS.
  • a polyglucosamin selected from the group consisting of chitin, chitosan, polyglucosaminoglycans, chondroitin, heparin, keratan and dermatan or a derivative thereof
  • a polymerized silane-PEG-NH2 a polymerized silane comprising an amino group,
  • the polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group is selected from the group consisting of chitin, chitosan, polyglucosaminoglycans, chondroitin, heparin, keratin, dermatan or a derivative thereof, in particular chitosan or a derivative thereof, a polymerized silane-PEG-NH2 selected from the group consisting of polymerized silane-PEG4- NH2, polymerized silane-PEG2000-NH2, polymerized silane-PEG5000-NH2, a polymerized silane comprising an amino group which is APTES and a polymerized silane comprising an thiol group which is MPTS.
  • a polymer comprising repeat units wherein each repeat unit comprises at least one thiol group is selected from the group consisting of a polymerized silane comprising a thiol group, a polycarbophil-cysteine conjugate, a polymerized silane-PEG-thiol and a polycysteine, and is preferably selected from the group consisting of a polymerized silane comprising a thiol group, a polycarbophil-cysteine conjugate, and a polymerized silane-PEG- thiol, and is more preferably a polymerized silane comprising a thiol group, and is most perferably polymerized MPTS.
  • a polymerized silane comprising a thiol group is preferably polymerized MPTS.
  • 5% to 100%, preferably 10% to 100%, more preferably 50% to 100%, of the surface of the protective layer is covered with a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group.
  • the optional functional constituent is immobilized on the surface of the protective layer by binding, preferably covalent binding.
  • the optional functional constituent is immobilized on the surface of the protective layer by non- covalent binding, preferably by electrostatic interactions.
  • the polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group is immobilized on the surface of the protective layer by covalent binding.
  • the optional functional constituent is immobilized on the surface of the protective layer using a spacer binding to the surface of the protective layer and the functional constituent.
  • the present invention comprises a composition comprising a solid carrier, a protein or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the protein or a fragment thereof by embedding the protein or a fragment thereof, and optionally a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group, wherein the functional constituent is immobilized on the surface of the protective layer by a spacer.
  • a spacer examples include a polyethylene such as PEG4, PEG2000, PEG5000.
  • a functional constituent immobilized on the surface of the protective layer, by a spacer is usually produced by firstly reacting the spacer with the functional constituent, so that the spacer binds to the functional constituent and then the functional constituent bound to the spacer is reacted with the the surface of the protective layer.
  • the immobilization of the optional functional constituent to the surface of the protective layer is usually carried out in a reaction vessel like a reactor by suspending the solid carrier carrying the protein e.g. the enzyme embedded in a protective layer as described supra in e.g. in water, buffer or non-ionic surfactants or mixtures thereof, preferably in mixtures of water and nonionic surfactants.
  • Non-ionic surfactants are usually selected from the group consisting of ethoxylated sorbitan esters like PEG-40 sorbitan diisostearate, polysorbate 80 (PS80), polysorbate 20 (PS20), polysorbate 40 (PS40), polysorbate 60 (PS60); bock co-polymers like poloxamer 124, poloxamer 188, poloxamer 331, poloxamer 407, fatty acids ethoxylates like PEG-5 oleate, PEG-8 stearate, polyoxyl 40 stearate, polyoxyl 15 hydroxystearate, fatty alcohol ethoxylates like steareth 40; fatty acid esters like ascorbyl palmitate, beeswax, polyglyceryl 3- oleate, propylene glycol monocaprylate, propylene glycol monolaurate; fatty alcohols like cetostearyl alcohol, cetyl alcohol, myristic alcohol, stearyl alcohol; glycer
  • the functional component is then added to the suspension to react usually under stirring with the surface of the protetctive layer to immobilize the functional constitutent on the surface of the protective layer.
  • Ususally such obtained composition is washed and resuspended into water, buffer or non-ionic surfactants or mixtures thereof. Immobilization takes place by non-covalent binding e.g. electrostatic binding or by covalent binding of the functional constituent, t.
  • the functional constituent may be immobilized by chemically modifying the surface of the protective layer and the functional constituent using e.g. “click chemistry” such as copper-catalyzed click chemistry (Copper-catalysed azide-alkyne cycloaddition, see e.g. Kolb et al.
  • the solid carrier carrying the protein e.g. the enzyme embedded in a protetctive layer as described supra is first reacted with a reactive compound like an ethynyl compound and the functional constituent is modified by adding a reactive compound e.g. an azide residue and then both components are reacted to immobilize the functional constituent on the surface of the protective layer.
  • the present invention provides the composition as described herein for use as a medicament.
  • the present invention provides the composition as described herein for use in a method of enzyme replacement therapy (ERT), preferably gastrointestinal enzyme replacement therapy, or for use in a method for the prevention, delay of progression or treatment of exocrine pancreatic insufficiency (EPI).
  • ERT enzyme replacement therapy
  • EPI exocrine pancreatic insufficiency
  • the present invention provides the composition for use in a method for the prevention, delay of progression or treatment of exocrine pancreatic insufficiency (EPI).
  • the present invention provides the composition for use in a method of enzyme replacement therapy (ERT), preferably gastrointestinal enzyme replacement therapy.
  • composition as described herein for the manufacture of a medicament for the prevention, delay of progression or treatment of exocrine pancreatic insufficiency (EPI) in a subject. Also provided is the use of the composition as described herein for the prevention, delay of progression or treatment of exocrine pancreatic insufficiency (EPI) in a subject. Also provided is a method for the prevention, delay of progression or treatment of exocrine pancreatic insufficiency (EPI) in a subject, comprising administering to said subject a therapeutically effective amount of the composition as described herein. Also provided herein is the use of the composition as described herein for the manufacture of a medicament for a method of enzyme replacement therapy (ERT), preferably gastrointestinal enzyme replacement therapy.
  • ERT enzyme replacement therapy
  • compositions as described herein in a method of enzyme replacement therapy (ERT), preferably gastrointestinal enzyme replacement therapy in a subject. Also provided is a method of enzyme replacement therapy (ERT), preferably gastrointestinal enzyme replacement therapy, in a subject, comprising administering to said subject a therapeutically effective amount of the composition as described herein.
  • ERT enzyme replacement therapy
  • ERT preferably gastrointestinal enzyme replacement therapy
  • the present invention provides the composition as described herein for use in a method for the prevention, delay of progression or treatment of phenylketonuria (PKU). Also provided is the use of the composition as described herein for the manufacture of a medicament for the prevention, delay of progression or treatment of phenylketonuria (PKU) in a subject. Also provided is the use of the composition as described herein for the prevention, delay of progression or treatment of phenylketonuria (PKU) in a subject. Also provided is a method for the prevention, delay of progression or treatment of phenylketonuria (PKU) in a subject, comprising administering to said subject a therapeutically effective amount of the composition as described herein. Preferably, the composition when administered to a subject in the method of the invention degrades phenylalanine in the intestine of the subject.
  • the present invention provides the composition as described herein for use in a method for the prevention, delay of progression or treatment of lactase deficiency, sucrase- isomaltase deficiency, and/or disaccharidoses intolerances.
  • the present invention provides the composition for use in a method for the prevention, delay of progression or treatment of lactase deficiency or sucrase-isomaltase deficiency.
  • Lactase deficiency includes primary (hereditary) lactase deficiency, secondary (acquired) lactase deficiency and congenital lactase deficiency and is preferably secondary lactase deficiency.
  • Sucrase-isomaltase deficiency includes Congenital Sucrase-isomaltase Deficiency (CSID) which is preferred.
  • CCD Congenital Sucrase-isomaltase Deficiency
  • the composition as described herein for the manufacture of a medicament for the prevention, delay of progression or treatment of lactase deficiency, sucrase-isomaltase deficiency, and/or disacchari doses intolerances in a subject.
  • the composition as described herein for the prevention, delay of progression or treatment of lactase deficiency, sucrase-isomaltase deficiency, and/or disacchari doses intolerances in a subject.
  • a composition according to the invention is preferably a pharmaceutical composition and comprises a therapeutically effective amount of the composition as described herein and one or more suitable pharmaceutically acceptable carrier.
  • a pharmaceutical composition according to the invention is suitable for oral administration to a subject. If not indicated otherwise, a pharmaceutical composition according to the invention is prepared in a manner known per se.
  • the composition e.g. the pharmaceutical composition of the invention may be administered according for a continuous period of one week or a part thereof, for two weeks, for three weeks for four weeks, for five weeks or for six weeks and then stopped for a period of one week, or a part thereof, for two weeks, for three weeks, for four weeks, for five weeks, or for six weeks.
  • the composition, e.g. the pharmaceutical composition of the present invention may conveniently be administered in unit dosage forms. Units ("U") of enzyme activity can be described in terms of weight or mass of substrate hydrolyzed per unit time.
  • an effective amount or “therapeutically effective amount” as used herein refers to an amount capable of invoking one or more of the desired effects in a subject receiving the composition of the present invention. Determination of a therapeutically effective amount is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
  • treatment includes: (1) delaying the appearance of clinical symptoms of the state, disorder or condition developing in an animal, particularly a mammal and especially a human, that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition; (2) inhibiting the state, disorder or condition (e.g. arresting, reducing or delaying the development of the disease, or a relapse thereof in case of maintenance treatment, of at least one clinical or subclinical symptom thereof); and/or (3) relieving the condition (i.e. causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms).
  • the benefit to a patient to be treated is either statistically significant or at least perceptible to the patient or to the physician. However, it will be appreciated that when a medicament is administered to a patient to treat a disease, the outcome may not always be effective treatment.
  • delay of progression means increasing the time to appearance of a symptom of or slowing the increase in severity of a symptom. Further, “delay of progression” as used herein includes reversing or inhibition of disease progression. “Inhibition" of disease progression or disease complication in a subject means preventing or reducing the disease progression and/or disease complication in the subject.
  • Preventive treatments comprise prophylactic treatments.
  • the pharmaceutical combination of the invention is administered to a subject suspected of having, or at risk for developing the above mentioned diseases or disorders.
  • the pharmaceutical combination is administered to a subject such as a patient already suffering from the above mentioned diseases or disorders, in an amount sufficient to cure or at least partially arrest the symptoms of the disease. Amounts effective for this use will depend on the severity and course of the disease, previous therapy, the subject's health status and response to the drugs, and the judgment of the treating physician.
  • the pharmaceutical combination of the invention may be administered chronically, which is, for an extended period of time, including throughout the duration of the subject's life in order to ameliorate or otherwise control or limit the symptoms of the subject's disease or condition.
  • the pharmaceutical combination may be administered continuously; alternatively, the dose of drugs being administered may be temporarily reduced or temporarily suspended for a certain length of time (i.e., a “drug holiday”).
  • a maintenance dose of the pharmaceutical combination of the invention is administered if necessary.
  • the dosage or the frequency of administration, or both is optionally reduced, as a function of the symptoms, to a level at which the improved disease is retained.
  • the present invention provides a composition
  • a composition comprising a solid carrier, a protein or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the protein or a fragment thereof by embedding the protein or a fragment thereof, and optionally a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group, wherein the composition is obtainable by the methods described supra.
  • the present invention provides a composition
  • a composition comprising a solid carrier, a protein or a fragment thereof immobilized on the surface of the solid carrier, a protective layer to protect the protein or a fragment thereof by embedding the protein or a fragment thereof, and optionally a functional constituent immobilized on the surface of the protective layer, wherein the functional constituent immobilized on the surface of the protective layer is a polymer comprising repeat units wherein each repeat unit comprises at least one amino group and/or at least one thiol group, wherein the composition is obtainable by the methods described supra; with the proviso that the protein or a fragment thereof is not a lipase or a fragment thereof, a protease or a fragment thereof, an amylase or a fragment thereof, pancreatin or a protein or a fragement thereof comprised by pancreatin, an engineered phenylalanine ammonia lyase (PAL) or a fragment thereof, and a disaccharidase or a fragment thereof,
  • Solid carrier, protein or a fragment thereof, protective layer to protect the protein or a fragment thereof and the optional functional constituent of the composition are as described supra.
  • TEOS Tetraethyl orthosilicate 99%
  • APTES (3-aminopropyl)-triethoxysilane
  • ammonium hydroxide ACS grade, 28-30%)
  • ethanol ACS grade, anhydrous
  • glutaraldehyde grade I, 25% in water
  • polysorbate 80 acetic acid
  • bovine serum albumin BSA
  • Tris buffer L- Phenylalanine
  • pancreatin pronase were purchased from Sigma- Aldrich.
  • BSA bovine serum albumin
  • pronase were purchased from Sigma- Aldrich.
  • BSA pancreatin, and pronase were dissolved in water to reconstitute the stock buffer.
  • - Engineered PAL (SEQ ID NO: 5) was provided by Nestle Health Science at a concentration of 90 mg/mL in 25 mM Sodium Phosphate, 250 mM Sodium Chloride, 5% D-Mannitol, 0.2% Poloxamer 188, pH 7.5.
  • Altromin 1324 was purchased at Altromin international.
  • Silica nanoparticles (50 nm) have been synthetized following the original Stober process as described in WO2015/014888 AL Briefly, ethanol, distilled water (6 M) and ammonium hydroxide (0.13 M) were mixed and stirred at 400 rpm for 1 h. TEOS (0.28 M) was added, and the solution was stirred at 400rpm at 20°C for 22h. The solution was then centrifuged at 20000 g for 20 min and washed successively with ethanol and water. Particle size measurement was carried out on SEM micrographs acquired at a magnification of 150000x using the image analysis software Olympus stream motion.
  • An organosilica layer was grown at the surface of the immobilized engineered PAL using APTES (7.7 mM) and TEOS (80.8 mM). The resulting suspension was allowed to react for 5 hours at 20°C, 400 rpm. The particles were washed 3 times (by centrifugation during 5 min at 20000 ref) in H 2 O/PS80 (8 mg/L) and resuspended in H 2 O/PS80 (8 mg/L). A solution of chitosan in acetic acid (0.1 M) was added to the particle suspension to achieve a final chitosan concentration of 121 pg/mL. The reaction mixture was allowed to react for 30 min at 20°C, 400 rpm. The particles were centrifuged 5 min at 20000 ref and washed 3 times in NaCl (0.9%)/PS80 (8 mg/L). NP-1 was cured overnight in a water bath at 20°C.
  • An organosilica layer was grown at the surface of the immobilized BSA using APTES (7.5 mM) and TEOS (75.4 mM). The resulting suspension was allowed to react for 5 hours at 20°C, 400 rpm. The particles were washed 3 times (by centrifugation during 5 min at 20000 ref) in H 2 O/PS80 (8 mg/L) and resuspended in H 2 O/PS80 (8 mg/L). A solution of chitosan in acetic acid (0.1 M) was added to the particle suspension to achieve a final chitosan concentration of 121 pg/mL. The reaction mixture was allowed to react for 30 min at 20°C, 400 rpm. The particles were centrifuged 5 min at 20000 ref and washed 3 times in NaCl (0.9%)/PS80 (8 mg/L). NP-2 was cured overnight in a water bath at 20°C.
  • PAL-based silica nanoparticles (NP-l(l)) were produced in H 2 O/PS80 (8 mg/L). Nanoparticles were washed after each chemical step resulting in glutaraldehyde removal. To SNPs (10 mg/mL, 59 nm) in H 2 O/PS80 (8 mg/L) was added APTES (3.9 mM). The reaction mixture was allowed to react for 10 min at 20°C, 400 rpm. Particles were washed three times in H 2 O/PS80 (8 mg/L) and resuspended in H 2 O/PS80 (8 mg/L).
  • Engineered PAL (11.9 mg/mL, 1 mM) was added, and the reaction mixture was allowed to react for 10 min at 20°C, 400 rpm.
  • An organosilica layer was grown at the surface of the immobilized engineered PAL using APTES (7.7 mM) and TEOS (80.8 mM).
  • the resulting suspension was allowed to react for 5 hours at 20°C, 400 rpm.
  • the particles were washed 3 times (by centrifugation during 5 min at 20000 ref) in H 2 O/PS80 (8 mg/L) and resuspended in H 2 O/PS80 (8 mg/L).
  • a solution of chitosan in acetic acid (0.1 M) was added to the particle suspension to achieve a final chitosan concentration of 121 pg/mL.
  • the reaction mixture was allowed to react for 30 min at 20°C, 400 rpm.
  • the particles were centrifuged 5 min at 20000 ref and washed 3 times in H 2 O/PS80 (8 mg/L).
  • NP-l(l) were cured overnight in a water bath at 20°C.
  • PAL-based silica nanoparticles (NP-1 (2)) in buffer. Nanoparticles were washed after each chemical step resulting in glutaraldehyde removal.
  • SNPs (10 mg/mL, 59 nm) in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L) was added APTES (3.9 mM). The reaction mixture was allowed to react for 10 min at 20°C, 400 rpm.
  • Particles were washed three times in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L) and resuspended in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L). Then, glutaraldehyde (3.9 mM) was added, and the reaction mixture was stirred for 10 min at 20°C, 400 rpm. Particles were washed three times in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L) and resuspended in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L).
  • a priming was performed by adding APTES (3.9 mM) and stirring the reaction mixture for 10 min at 20°C, 400 rpm. Particles were washed three times in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L) and resuspended in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L). Engineered PAL (11.9 mg/mL, 1 mM) was added, and the reaction mixture was allowed to react for 10 min at 20°C, 400 rpm. An organosilica layer was grown at the surface of the immobilized engineered PAL using APTES (7.7 mM) and TEOS (80.8 mM).
  • the resulting suspension was allowed to react for 5 hours at 20°C, 400 rpm.
  • Particles were washed three times in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L) and resuspended in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L).
  • a solution of chitosan in acetic acid (0.1 M) was added to the particle suspension to achieve a final chitosan concentration of 121 pg/mL.
  • the reaction mixture was allowed to react for 30 min at 20°C, 400 rpm.
  • NP-1(2) were cured overnight in a water bath at 20°C.
  • PAL-based silica nanoparticles were produced in H 2 O/PS80 (8 mg/L) according to the section headed “Production of NP-1” above.
  • glutaraldehyde which has not linked the solid carrier to the engineered PAL in the reaction mixture, the nanoparticles were not washed between each chemical step. Therefore, glutaraldehyde was still present during layer growth and caused a covalent binding of the protective layer to the engineered PAL.
  • the covalent binding of the protective layer to the engineered PAL can be observed by the appearance of a yellow/orange color that has an absorbance maximum at 460 nm.
  • This color is due to the formation of an imine bond by reaction between the aldehyde functions of the glutaraldehyde linker and the primary amines of the amino acids of the engineered PAL and the organosilica layer.
  • the absorbance of PALbased silica nanoparticles NP-l(l), NP-1 (2), and NP-1 at 460 nm was measured after the organosilica layer formation and final particles washing i.e.
  • NP-1 Phenylalanine Ammonia Lyase Immobilization and Protection “ above, showing a much higher absorbance at 460 nm for NP-1 than for NP-l(l) and NP-1(2) (see Figure 8).
  • NP-l(l) and NP-1(2) still show absorbance to some degree at this wavelength, as imine bonds are also formed during enzyme immobilization.
  • the absorbance of NP-1 is significantly higher indicating an additional formation of imine bonds caused by covalent binding of the protective layer to the engineered PAL.
  • Engineered PAL or PAL-based silica nanoparticles NP-1 were incubated at pH4 over a period of 24. The enzymatic activity was assessed at 0, 1, 3, 6 and 24h as described in “Activity assay ofNP-1”
  • NP-1 Engineered PAL or PAL-based silica nanoparticles NP-1 were treated with pancreatin (30mU) or pronase (0.8U) and incubated at 37°C under shaking at 300rpm over a period of 4h. The enzymatic activity was assessed at 0, 0.1, 0.25, 0.5, 1, 2 and 4h as described in “Activity assay ofNP-1”-
  • Caco2 human colorectal adenocarcinoma cell line
  • HT29-MTX-E12 human colon cancer cell line
  • DMEM fetal calf serum
  • 2mM L-glutamine 10% heat-inactivated fetal calf serum
  • 2mM L-glutamine 10% non-essential amino-acid
  • 100 U/mL penicillin/streptomycin 100 U/mL penicillin/streptomycin.
  • cells were seeded at a density of 2.6 x 10 5 cells/cm 2 in transwell PET inserts (1pm pore size). All cell models were used for experiments on day 21.
  • Caco-2 and HT-29-MTX-E12 cells were used at a ratio 75%-25%.
  • the integrity of the cell barrier was assessed by the measurement of the transepithelial electrical resistance (TEER) using the CellZscope system (NanoAnalytics). After cell culture medium refreshment and treatment with nanoparticles, automated measurements of the TEER for up to 24h every 15 minutes with a range from 1Hz to lOO’OOOHz.
  • TEER transepithelial electrical resistance
  • the intestinal barrier was exposed to PAL-based silica nanoparticles NP-1 (9.7mU) or engineered PAL (9.7mU) in presence of pancreatin (30mU) for 6h at the apical side of the barrier.
  • aliquots of 150uL were withdrawn from the basolateral sides of the intestinal barrier and replaced with the same volume of pre-warmed cell medium.
  • the barrier was further incubated at 37°C.
  • the absorbance of the withdrawn aliquot samples was measured at 290nm to quantify the level of trans-cinnamic acid (TCA).
  • the rats were fed with a pelleted complete diet “Altromin 1324” available ad libitum. They had access ad libitum to drinking water. o Duodenum catheterization
  • mice were starved for 4h. Then, rats were dosed intraduodenally with NP-1 (0.85U) or NP-2 (8.5mg) and immediately gavaged with 3,6mg of d5-L-Phe. Rats were hosted in metabolic cage for 24h. o Urine sampling, metabolic cages
  • Urine was collected in metabolic cages for 24h. The total urine output was obtained, and the urine was sampled in Eppendorf tubes and stored at -80°C until shipped for analysis. o Measurement d5-hippuric acid in urine of rats:
  • Urine samples were prepared as follow: 50uL of urine sample were spiked on5uL of ISTD (lOOpM 13C6-HIP, final cone. 2pM in each sample), and 200uL of 100% methanol was added before vortexing. After 20min on ice, samples were centrifugated for 10 min at 16000g at 4°C.The supernatant was transferred into total recovery MS glass vials for analysis.
  • the MS was performed by using the mass spectrometer Thermo Q Exactive with the acquisition mode DDA top5.
  • the MS parameters were the following: MSI resolution: 70'000 and MS2 resolution: 17' 500.
  • the HCD fragmentation was performed with normalized stepped collision energy 10, 20 and 30. Data analysis was performed in Thermo quan Browser software.
  • mice Male and female BTBR-Pah enu2 /J mice (8 weeks of age) of the stock from The Jackson Laboratory, USA.
  • Diet and drinking water The mice were fed with a phenylalanine free diet (5LF2, LabDiet) available ad libitum. They had access ad libitum to drinking water.
  • o Duodenum catheterization 5LF2, LabDiet
  • mice were anesthetized with isoflurane (2-4%). An incision was made to open the abdominal cavity through the linea alba, and a catheter (C19PB-MGI1923, Instech Laboratories) was placed in the duodenum through the antimesenteric side of the duodenum. The tip of the catheter was advanced and positioned close to the opening of the biliopancreatic duct. The catheter was ligated to the intestinal wall and tunneled subcutaneously to the neck of the animals where it was exteriorized and closed. The abdominal wall and the incision in the neck were thereafter closed with sutures. The animals were kept on a warm bed during the entire procedure and will be closely monitored until fully recovered from anesthesia. o Evaluation of PAL-based silica nanoparticles NP-1 efficacy in mice
  • mice were maintained under phenylalanine free diet for at least 3 days, then the drinking water was supplemented with L-Phe at low concentration (0.03g/L) for 3 days, after which the concentration of L-Phe was increased in the drinking water to 0.5g/L. Mice had access to L-Phe supplemented drinking water ad libitum during the night phase.
  • mice were dosed intraduodenally with NP-1 (0.581U, 7mg), NP-2 (7mg) or engineered PAL (0.581U) twice per day over a period of 12 days. Blood samples were taken in EDTA at days 0, 4, 6, 8, 10 and 12. Blood samples were then centrifuged (10 min, 4°C, 2000 x g), and a minimum of 20 uL plasma was transferred into Eppendorf tubes and stored at -80°C until analysis for Phe content. o Measurement of plasmatic Phe of mice:
  • Quantification of analytes of interest was performed using the LC system: Thermo Vanquish Horizon Binary Pump and the mass spectrometer: Thermo TSQ Quantiva.
  • Plasma samples were prepared as follows: 20uL of plasma sample were centrifuged at 13.2krpm for 10 min at 4°C. Ten microliters of supernatant were added to lOuL of ISTD (lOOOpM D5-Phe) and 80pL 100% MeOH. The samples were then vortex and centrifuged at 13.2krpm for 10 min at 4°C, after which 50uL of supernatant were dried under a gentle stream of nitrogen at 30°C. Five hundred microliters of 0.1% (v/v) formic acid in water were added and the samples were shaked at 900rpm for lOmin at 15°C before centrifugation (13.2krpm for 10 min at 4°C). Finally, 350uL of supernatant were transferred into total recovery glass vials for analysis.
  • the MS is performed by using the mass spectrometer Thermo TSQ Quantiva with the acquisition mode: Selected reaction monitoring.
  • the MS parameters were the following: Q ⁇ 1 resolution: 0.7; Q3 resolution: 0.7; frangmentation: CID fragmentation with argon (1.5mTorr).
  • the analyte concentration was calculated from the peak area ratio of Phe to the internal standard d5-Phe. Data analysis was performed in Thermo quan Browser software.
  • Example 1 Enhancing PAL Stability through Covalent Attachment to the protective layer
  • PAL-based silica nanoparticles NP-l(l) were produced in non-buffered conditions and included washing after each chemical step (i.e. glutaraldehyde removal before layer growth).
  • PAL-based silica nanoparticles NP-1(2) were produced in buffered conditions and included washing after each chemical step (i.e. glutaraldehyde removal before layer growth).
  • PAL-based silica nanoparticles NP-1 were produced in non-buffered conditions without any intermediate washing steps (i.e. unreacted glutaraldehyde still present in the reaction mixture during layer growth).
  • the biocatalytic activity of PAL immobilized and protected on NP-l(l), NP-1 (2), and NP-1 was evaluated. Even more surprisingly than the increase in load by the enzyme immobilization where the presence of glutaraldehyde is maintained, was the threefold increase in nanoparticle specific activity compared to buffered conditions where glutaraldehyde is removed by washing steps and the two times increase compared to unbuffered conditions where glutaraldehyde is removed by washing steps (Fig. 2C).
  • Example 2 Phenylalanine ammonia lyase (PAL) activity of PAL-based silica nanoparticles NP-1
  • the biocatalytic activity of immobilized and protected engineered PAL was assessed.
  • the result as displayed in figure 3 reports a PAL activity on NP-1. This shows the ability of the shielded functionalized SNP to access and to convert L-Phe despite the shield and the functionalization.
  • the validation of the biocatalytic activity on NP-1 confirms the possibility of using the nanoparticles for therapeutic purposes.
  • PAL-based silica nanoparticle NP-1 is a nanoparticle that has been developed for gastrointestinal applications. Due to the physiological properties of the gastrointestinal tract, NP-1 will be submitted to various stresses. To ensure a sustained activity of NP-1 in the gastrointestinal tract, the protection of immobilized engineered PAL was assessed. First, NP-1 or engineered PAL were submitted to acidic conditions (pH4). The monitoring of the PAL activity over a period of 24h reveals a sustained enzymatic activity on NP-1 (Fig.4B) while the free form of engineered PAL loses its activity over the time (Fig.4A). These data demonstrated the protection of the immobilized and protected engineered PAL on NP-1 in an acidic environment.
  • NP-1 and engineered PAL were exposed to various proteases at 37°C.
  • the PAL activity was assessed after coincubation of NP-1 or engineered PAL with pancreatin (30mU), a mixture of pancreatic enzymes extracted from porcine pancreas. After 4h, both NP- 1 and engineered PAL show a sustained PAL activity (Fig.4C). Then, to further evaluate the benefits of the protective shield in harsh conditions, NP-1 or engineered PAL were exposed to pronase (0.88U), a cocktail of purified proteases.
  • Example 4 In vitro biocompatibility and efficacy of PAL-based silica nanoparticles NP-1
  • the maintenance of the integrity of the intestinal barrier is fundamental to prevent undesirable luminal contents such as pathogens or food allergens from entering in the body.
  • Caco2-HT29-MTX-E12 cell monolayers were exposed to NP-1 in presence or not of pancreatin to mimic digestive conditions and the transepithelial electrical resistance (TEER) was measured.
  • TEER transepithelial electrical resistance
  • Data shown on figure 5 A report a maintenance of the integrity of the intestinal epithelial barrier when in contact with NP-1 with or without pancreatin for 6h. This result demonstrates the in vitro biocompatibility of NP-1 for gastrointestinal applications.
  • NP-1 has been developed to metabolize Phe in the lumen of the intestine.
  • Caco2-HT29-MTX-E12 cell monolayers cultivated in cell medium containing 0.4mM of L-Phe were exposed at their apical side to NP-1 (9.7mU) or engineered PAL (9.7mU) in presence or not of pancreatin (30mU) for 6h.
  • the quantification of the product of Phe metabolization in the basal side of the barrier is shown on figure 5B.
  • the graph reports an accumulation of TCA in the basolateral side of the barrier in all conditions. This result demonstrates the in vitro efficacy of NP-1 in a digestive environment and suggests the use of NP-1 for therapeutic applications.
  • Example 5 In vivo activity of PAL-based silica nanoparticles NP-1 in rats
  • NP-1 neuropeptide-1
  • Rats were dosed intraduodenally with NP-1 (nanoparticles comprising engineered PAL) or NP-2 (nanoparticles comprising bovine serum albumin (BSA) for which Phe is not a substrate) prior being gavaged with d5-Phe.
  • BSA bovine serum albumin
  • TCA the product of Phe metabolization
  • TCA is rapidly metabolized into hippuric acid.
  • the in vivo activity of NP-1 was then evaluated by the quantification of d5-hippuric acid in rat urine collected for 24h post dosing.
  • Example 6 In vivo therapeutic efficacy of PAL-based silica nanoparticles NP-1 in mice Phenylketonuria (PKU) is characterized by a deficiency in the intracellular liver enzyme phenylalanine hydroxylase (PAH). PAH catalyzes the conversion of the essential amino acid phenylalanine to tyrosine. PAH deficiency results in an abnormally elevated concentrations of phenylalanine, which is toxic to the brain.
  • the cornerstone of PKU treatment is a low phenylalanine diet in combination with phenylalanine-free L-amino acid.
  • an enzyme substitution therapy with recombinant phenylalanine ammonia lyase is available for subcutaneous injections, but this treatment induces hypersensitivity reactions and immune- mediated acute hypersensitivity reactions.
  • NP-1 has been developed to exhibit a sustained PAL activity in gastrointestinal environment (acidity and exposure to proteases).
  • Our approach to control the Phe level in patients is to degrade the Phe in the intestine (from food intake) to avoid its absorption and its accumulation in the blood.
  • mice having access to L-Phe supplemented drinking water were dosed twice a day with NP-1, NP-2 or engineered PAL over 12 days.
  • NP-1 NP-1
  • NP-2 NP-2
  • engineered PAL PAL
  • a steady decrease of Phe plasmatic level is reported in mice dosed with NP-1 over the period of the study, while the plasmatic concentration of mice dosed with engineered PAL is unstable (Fig.7).
  • the normalization of the plasmatic concentration of Phe as presented on Fig.7B highlights a decrease of 30% of plasmatic Phe concentration in mice at the end of the treatment with NP-1.
  • TEOS Tetraethyl orthosilicate 99%
  • APTES (3-aminopropyl)-triethoxysilane
  • ammonium hydroxide ACS grade, 28-30%)
  • ethanol ACS grade, anhydrous
  • glutaraldehyde grade I, 25% in water
  • polysorbate 80 acetic acid
  • lactase USP reference standard
  • invertase bovine serum albumin
  • BSA bovine serum albumin
  • PMA phorbol 12-myristate 13 -acetate
  • BSA lactase and invertase were dissolved in water to reconstitute the stock buffer.
  • Caco-2 human colorectal adenocarcinoma cell line
  • HT29-MTX-E12 human colon cancer cell line
  • ECACC European Collection of Authenticated Cell Cultures
  • THP-1 human acute monocytic leukemia cell line
  • Silica nanoparticles (50 nm) have been synthetized following the original Stober process as described in WO2015/014888 Al. Briefly, ethanol, distilled water (6 M) and ammonium hydroxide (0.13 M) were mixed and stirred at 400 rpm for 1 h. TEOS (0.28 M) was added, and the solution was stirred at 400rpm at 20°C for 22h. The solution was then centrifuged at 20000 g for 20 min and washed successively with ethanol and water. Particle size measurement was carried out on SEM micrographs acquired at a magnification of 150000x using the image analysis software Olympus stream motion.
  • An organosilica layer was grown at the surface of the immobilized lactase using APTES (8.4 mM) and TEOS (125.9 mM). The resulting suspension was allowed to react for 5 hours at 20°C, 400 rpm. The particles were washed 3 times (by centrifugation during 5 min at 20000 ref) in H2O/PS80 (8 mg/L) and resuspended in H2O/PS80 (8 mg/L). A solution of chitosan in acetic acid (0.1 M) was added to the particle suspension to achieve a final chitosan concentration of 121 pg/mL. The reaction mixture was allowed to react for 30 min at 20°C, 400 rpm. The particles were centrifuged 5 min at 20000 ref and washed 3 times in NaCl (0.9%)/PS80 (8 mg/L). NP-2 was cured overnight in a water bath at 20°C.
  • Lactase-based silica nanoparticles NP-2 variants are Lactase-based silica nanoparticles NP-2 variants:
  • lactase-based silica nanoparticles (NP-2(1)) were produced in H 2 O/PS80 (8 mg/L). Nanoparticles were washed after each chemical step resulting in glutaraldehyde removal. To SNPs (10 mg/mL, 69 nm) in H 2 O/PS80 (8 mg/L) was added APTES (3.3 mM). The reaction mixture was allowed to react for 10 min at 20°C, 400 rpm. Particles were washed three times in H 2 O/PS80 (8 mg/L) and resuspended in H 2 O/PS80 (8 mg/L).
  • Lactase (5.2 mg/mL, 0.1 mM) was added, and the reaction mixture was allowed to react for 10 min at 20°C, 400 rpm.
  • An organosilica layer was grown at the surface of the immobilized lactase using APTES (6.5 mM) and TEOS (93 mM).
  • the resulting suspension was allowed to react for 5 hours at 20°C, 400 rpm.
  • the particles were washed 3 times (by centrifugation during 5 min at 20000 ref) in H 2 O/PS80 (8 mg/L) and resuspended in H 2 O/PS80 (8 mg/L).
  • NP-2(1) were cured overnight in a water bath at 20°C.
  • Particles were washed three times in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L) and resuspended in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L). Then, glutaraldehyde (3.3 mM) was added, and the reaction mixture was stirred for 10 min at 20°C, 400 rpm. Particles were washed three times in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L) and resuspended in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L).
  • a priming was performed by adding APTES (3.3 mM) and stirring the reaction mixture for 10 min at 20°C, 400 rpm. Particles were washed three times in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L) and resuspended in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L). Lactase (5.2 mg/mL, 0.1 mM) was added, and the reaction mixture was allowed to react for 10 min at 20°C, 400 rpm. An organosilica layer was grown at the surface of the immobilized lactase using APTES (6.5 mM) and TEOS (93 mM).
  • NP-2(2) were cured overnight in a water bath at 20°C.
  • lactase-based silica nanoparticles were produced in H 2 O/PS80 (8 mg/L) according to the section headed “Production of NP-2” above.
  • glutaraldehyde which has not linked the solid carrier to the lactase in the reaction mixture, the nanoparticles were not washed between each chemical step. Therefore, glutaraldehyde was still present during layer growth and caused a covalent bonding of the protective layer to the lactase.
  • the covalent binding of the protective layer to lactase can be observed by the appearance of a yellow/orange colour that has an absorbance maximum at 460 nm.
  • NP-2(1) and NP-2(2) still show absorbance to some degree at this wavelength, as imine bonds are also formed during enzyme immobilization. However, the absorbance of NP-2 is significantly higher indicating an additional formation of imine bonds caused by covalent binding of the protective layer to lactase.
  • An organosilica layer was grown at the surface of the immobilized invertase using APTES (5.4 mM) and TEOS (81.3 mM). The resulting suspension was allowed to react for 5 hours at 20°C, 400 rpm. The particles were washed 3 times (by centrifugation during 5 min at 20000 ref) in H2O/PS80 (8 mg/L) and resuspended in H2O/PS80 (8 mg/L). A solution of chitosan in acetic acid (0.1 M) was added to the particle suspension to achieve a final chitosan concentration of 115 pg/mL. The reaction mixture was allowed to react for 30 min at 20°C, 400 rpm. The particles were centrifuged 5 min at 20000 ref and washed 3 times in NaCl (0.9%)/PS80 (8 mg/L). NP-3was cured overnight in a water bath at 20°C.
  • An organosilica layer was grown at the surface of the immobilized invertase using APTES (5.8 mM) and TEOS (88 mM). The resulting suspension was allowed to react for 5 hours at 20°C, 400 rpm. The particles were washed 3 times (by centrifugation during 5 min at 20000 ref) in H2O/PS80 (8 mg/L) and resuspended in H2O/PS80 (8 mg/L). A solution of chitosan in acetic acid (0.1 M) was added to the particle suspension to achieve a final chitosan concentration of 82 pg/mL. The reaction mixture was allowed to react for 30 min at 20°C, 400 rpm. The particles were centrifuged 5 min at 20000 ref and washed 3 times in H2O/PS80 (8 mg/L). NP-4 was cured overnight in a water bath at 20°C.
  • chitosan in acetic acid 0.1 M was added to the particle suspension to achieve a final chitosan concentration of 82 pg/mL.
  • the reaction mixture was allowed to react for 30 min at 20°C, 400 rpm.
  • the particles were centrifuged 5 min at 20000 ref and washed 3 times in H2O/PS80 (8 mg/L).
  • NP- 5 was cured overnight in a water bath at 20°C.
  • An organosilica layer was grown at the surface of the immobilized BSA using APTES (7.5 mM) and TEOS (75.4 mM). The resulting suspension was allowed to react for 5 hours at 20°C, 400 rpm. The particles were washed 3 times (by centrifugation during 5 min at 20000 ref) in H 2 O/PS80 (8 mg/L) and resuspended in H 2 O/PS80 (8 mg/L). A solution of chitosan in acetic acid (0.1 M) was added to the particle suspension to achieve a final chitosan concentration of 121 pg/mL. The reaction mixture was allowed to react for 30 min at 20°C, 400 rpm.
  • NP-l was cured overnight in a water bath at 20°C.
  • SNPs-BSA-AT were cured overnight at 20°C.
  • Lactase activity assay To a suspension of lactase-based silica nanoparticles NP-2 (30 pL, 2.3 mg/mL) in phosphate buffer (100 mM, pH 6.5)/MgCl 2 (5 mM) was added a lactose solution (100 pL, 50 mg/mL). The reaction mixture was incubated in a thermomixer for 20 minutes at 37°C, 750 rpm. Samples were collected every 2.5 minutes and the glucose formation was monitored using a blood glucose meter.
  • Invertase-based silica nanoparticles NP-3 activity was assessed using the Sigma invertase assay kit.
  • a IX reaction buffer (94 pL) was added to NP-3 (94 pL, 147 pg/L).
  • IX sucrose solution (11.76 pL) was added.
  • the reaction mixture was incubated for 20 minutes at 37°C, 300 rpm in a thermomixer.
  • the sample was centrifuged at 20000 ref for 5 min.
  • the supernatant was collected and 85 pL was transferred to a 96-well plate.
  • 90 pL of a master reaction mix (prepared by mixing an enzyme mix, a dye reagent, and the assay buffer) was added to each well.
  • the reaction mixture was incubated for 20 minutes in the dark at room temperature.
  • NP-4 activity was assessed using a glucose meter.
  • An isomaltose solution (25 pL, 100 mM) was equilibrated for 5 minutes at 37°C, 700 rpm.
  • NP-4 25 pL, 67 pg
  • phosphate buffer 50 mM, pH 6.8 The reaction mixture was incubated for 10 min at 37°C, 700 rpm. Samples were collected after 2 min, 5 min and 10 min and glucose concentrations were determined using a glucose meter.
  • NP-5 isomaltase activity was assessed using a glucose meter.
  • An isomaltose solution (25 pL, 100 mM) was equilibrated for 5 minutes at 37°C, 700 rpm.
  • NP-5 25 pL, 67 pg
  • phosphate buffer 50 mM, pH 6.8 The reaction mixture was incubated for 10 min at 37°C, 700 rpm. Samples were collected after 2 min, 5 min and 10 min and glucose concentrations were determined using a glucose meter.
  • NP-5 invertase activity was assessed using a glucose meter.
  • a sucrose solution 25 pL, 100 mM was equilibrated for 5 minutes at 37°C, 700 rpm.
  • NP-5 25 pL, 67 pg
  • phosphate buffer 50 mM, pH 6.8 The reaction mixture was incubated for 10 min at 37°C, 700 rpm. Samples were collected after 2 min, 5 min and 10 min and glucose concentrations were determined using a glucose meter.
  • Caco2 human colorectal adenocarcinoma cell line
  • HT29-MTX-E12 human colon cancer cell line
  • THP-1 Human monocytic leukaemia cell line
  • THP-1 differentiation into macrophages THP-1 cells were cultured in differentiation medium: RPMI 1640 with 10% heat-inactivated fetal calf serum, 2mM L-glutamine, 100 U/mL penicillin/streptomycin, lOmM HEPES, ImM sodium pyruvate, 2,5g/L glucose and 50pM 0- mercaptoethanol.
  • THP-1 were differentiated into MO-macrophages by 24h incubation with 150nM phorbol 12-myristate 13 -acetate (PMA) followed by 24h incubation in differentiation medium.
  • PMA phorbol 12-myristate 13 -acetate
  • the integrity of the cell barrier was assessed by the measurement of the transepithelial electrical resistance (TEER) using the CellZscope system (NanoAnalytics). After cell culture medium refreshment and treatment with nanoparticles, automated measurements of the TEER for up to 24h every 15 minutes with a range from 1Hz to lOO’OOOHz.
  • TEER transepithelial electrical resistance
  • the rats were fed with a pelleted complete diet “Altromin 1319” available ad libithum. They had access ad libitum to drinking water.
  • Animals were anesthetized with isoflurane (2-4%) in an induction chamber before being moved to a nose cone with isoflurane for the surgery.
  • a catheter (C30PU-RDD1444, Instech Laboratories) was placed in the duodenum on the antimesenteric side close to the opening of the biliopancreatic duct.
  • the catheter was ligated to intestinal wall and subcutaneously tunneled to the neck of the animals where it is exteriorized. The abdomen and the incision in the neck were thereafter closed with sutures. The animals were kept on heating during the entire procedure and closely monitored until fully recovered from anesthesia.
  • rats were dosed intraduodenally with lactase-based silica nanoparticles NP-2 (97U), inactive nanoparticles NP- l(54mg) or vehicle (l,5mL of NaC10,9%-polysorbate 80 8mg/mL) and immediately gavaged with 3g of lactose. Rats were daily dosed and gavaged over a period of 15 days.
  • Example 1 Enhancing Lactase Loading through Covalent Attachment to the protective layer
  • lactase-based silica nanoparticles NP-2(1) were produced in non-buffered conditions and included washing after each chemical step (i.e. glutaraldehyde removal before layer growth).
  • lactase-based silica nanoparticles NP-2(2) were produced in buffered conditions and included washing after each chemical step (i.e. glutaraldehyde removal before layer growth).
  • lactase-based silica nanoparticles NP-2 were produced in non-buffered conditions without any intermediate washing steps (i.e. unreacted glutaraldehyde still present in the reaction mixture during layer growth).
  • Lactase quantification was performed on the reaction supernatants to determine lactase immobilization yield at the surface of lactase-based silica nanoparticles NP-2(1), NP-2(2) and NP-2.
  • the results show that surprisingly enzyme immobilization under conditions where the presence of glutaraldehyde is maintained (NP-2) increases the enzyme immobilization yield by a factor of twenty-six (Fig. 10A), resulting in a 24-fold increase of enzyme loading per dry weight of SNP (Fig. 10B) compared to buffered conditions where glutaraldehyde is removed by washing steps (NP-2(2)).
  • NP-2 enzyme immobilization under conditions where the presence of glutaraldehyde is maintained (NP-2) results in a 2 times higher enzyme loading per dry weight of SNP (Fig. 10B) compared to unbuffered conditions where glutaraldehyde is removed by washing steps (NP-2(1)).
  • Example 2 Disaccharidases activity of lactase-based silica nanoparticles NP-2, invertasebased silica nanoparticles NP-3, isomaltase-based silica nanoparticles NP-4 and invertase/isomaltase-based silica nanoparticles NP-5
  • Example 3 Biocompatibility of the nanoparticles for gastrointestinal applications
  • the intestinal mucosa consists in a single layer of epithelial cells closely attached by intercellular tight junctions next to a subepithelial region that contains the lamina intestinal region. It acts as a barrier between the environment and the internal milieu. Its integrity is a key parameter to ensure the protection of the body against undesirable contaminants such as microorganisms.
  • the lamina propria includes a diffuse lymphoid tissue constituted by immune cells that maintain homeostasis or respond to a breakdown of epithelial protection.
  • NP-2 lactase-based silica nanoparticles NP-2 and invertase-based silica nanoparticles NP-3. It consists in inactive nanoparticles NP-1, a nanoparticle with the same functionalized outer surface as NP-2 and NP-3 but without enzymatic activity.
  • TEER transepithelial electrical resistance
  • FIG. 12B shows a decrease in integrity of the barrier in a dose dependant manner when treated with LPS, a proinflammatory component. This loss of integrity reveals the recruitments of macrophages from the basal to the apical side of the barrier.
  • NP-1 does not stimulate the recruitment of macrophages at the apical side of the intestinal barrier, and it can be concluded that NP- Idoes not induce inflammation.
  • Example 4 In vivo efficacy of lactase-based silica nanoparticles NP-2
  • Lactose malabsorption is attributable to an imbalance between the amount of ingested lactose and the capacity for lactase to hydrolyse the disaccharide. Digestion and absorption of lactose takes place in the small intestine. In case of lactose malabsorption, undigested lactose reaches the large intestine and comes into contact with the intestinal microbiota. The bacterial lactose fermentation leads to the production of short chain fatty acids and gasses resulting notably in an enlargement of the cecum.
  • Enzyme-replacement therapies with microbial exogenous lactase are available but the results about the exact rate of efficacy are discordant (Montalto et al., World J Gastroenterol 2006, Jan 14; 12(2): 187-91). Rules used to calculate the amount of lactase are 7500 units for 16 grams of lactose. Besides this close relationship between the amount of lactose to be hydrolysed and the enzyme units required, the stomach pH and bile salt concentrations influence the efficacy of exogenous lactase as well as the lack of specific localization of the enzyme in the intestine.
  • Example 5 In vitro efficacy of invertase-based silica nanoparticles NP-3
  • Congenital Sucrase-Isomaltase Deficiency is characterized by complete, or almost complete lack of sucrose activity and varying degrees of reduction in isomaltase activity.
  • the efficacy of invertase-based silica nanoparticles NP-3 to digest sucrose was assessed on a model of intestinal barrier. Differentiated Caco2-HT29-MTX-E12 cell monolayers were exposed at their apical side to NP-3 in presence of its substrate for 4h. The quantification of the product of sucrose hydrolysis in the basal compartment of the barrier is shown on Figure 14.
  • the graph reports a dose dependant accumulation of glucose in the basolateral side of the barrier in presence of increasing amount of invertase-based silica nanoparticles NP-3 while no glucose is detected in the untreated intestinal barrier. This result demonstrates the in vitro efficacy of invertase-based silica nanoparticles NP-3 and underlines the use of NP-3 for therapeutic applications.
  • TEOS 3 -aminopropyl)-triethoxy silane
  • APTES ammonium hydroxide
  • ethanol ACS grade, anhydrous
  • glutaraldehyde grade I, 25% in water
  • bovine serum albumin BSA
  • potassium phosphate monobasic, potassium phosphate dibasic, sodium taurocholate hydrate acetic acid, olive oil, gum arabic from acacia tree, sodium chloride, sodium hydroxide, Trizma base, hydrogen chloride, ammonium acetate, sodium acetate, pancreatin, bile salts, butanol, methanol, isopropanol, acetonitrile, NH4 acetate, amylase activity assay kit, 4% buffered formaline, Triton X-100 were purchased from Sigma- Aldrich
  • Altromin 1324 and Altromin 9033 were purchased at Altromine international
  • ZO-1 Antizonula occludens 1
  • goat anti-rabbit IgG conjugated to Alexa Fluor 488 and mounting medium containing DAPI were purchased at ThermoFischer Scientific.
  • Silica nanoparticles (50 nm) have been synthetized following the original Stober process as described in WO2015/014888 Al. Briefly, ethanol, distilled water (6 M) and ammonium hydroxide (0.13 M) were mixed and stirred at 400 rpm for 1 h. TEOS (0.28 M) was added, and the solution was stirred at 400rpm at 20°C for 22h. The solution was then centrifuged at 20000 g for 20 min and washed successively with ethanol and water. Particle size measurement was carried out on SEM micrographs acquired at a magnification of 150000x using the image analysis software Olympus stream motion.
  • glutaraldehyde (3.8 mM) was added, and the reaction mixture was stirred for 10 min at 20°C, 400 rpm.
  • a priming was performed by adding APTES (3.8 mM) and stirring the reaction mixture for 10 min at 20°C, 400 rpm.
  • a BSA solution was added to achieve a final BSA concentration of 1.42 mg/mL, and the reaction mixture was allowed to react for 10 min at 20°C, 400 rpm.
  • An organosilica layer was grown at the surface of the immobilized BSA using APTES (7.5 mM) and TEOS (75.4 mM). The resulting suspension was allowed to react for 5 hours at 20°C, 400 rpm.
  • the particles were washed 3 times (by centrifugation during 5 min at 20000 ref) in H 2 O/PS80 (8 mg/L) and resuspended in H 2 O/PS80 (8 mg/L).
  • a solution of chitosan in acetic acid (0.1 M) was added to the particle suspension to achieve a final chitosan concentration of 121 pg/mL.
  • the reaction mixture was allowed to react for 30 min at 20°C, 400 rpm.
  • the particles were centrifuged 5 min at 20000 ref and washed 3 times in NaCl (0.9%)/PS80 (8 mg/L).
  • NP-1 was cured overnight in a water bath at 20°C.
  • SNPs-BSA-AT were cured overnight at 20°C.
  • NP-2 Immobilization of the enzyme and shielding of the enzyme was conducted similar as described in W02015/014888:A1.
  • SNPs (10 mg/mL, 56 nm) in H 2 O/PS80 (8 mg/L) was added APTES (3.8 mM). The reaction mixture was allowed to react for 10 min at 20°C, 400 rpm. Then, DOTA (3.8 mM) was added and reacted for 1 hour at 50°C. DOTA-labeled particles were washed 3 times by centrifugation (20 min at 20000 ref) in H 2 O / PS80 (8 mg/L, Chelex), resuspended in H 2 O/PS80 (8 mg/L, Chelex) and tip sonicated.
  • APTES APTES
  • glutaraldehyde 3.8 mM
  • a priming was performed by adding APTES (3.8 mM) and stirring the reaction mixture for 10 min at 20°C, 400 rpm.
  • a BSA solution was added to achieve a final BSA concentration of 1.42 mg/mL, and the reaction mixture was allowed to react for 10 min at 20°C, 400 rpm.
  • An organosilica layer was grown at the surface of the immobilized BSA using APTES (7.5 mM) and TEOS (75.4 mM). The resulting suspension was allowed to react for 5 hours at 20°C, 400 rpm. The particles were centrifuged 5 min at 20000 ref and washed 3 times in NaCl (0.9%)/PS80 (8 mg/L). NP-2 was cured overnight in a water bath at 20°C.
  • An organosilica layer was grown at the surface of the immobilized pancreatin using APTES (7.7 mM), TEOS (40.4 mM) and benzyltriethoxysilane (35 mM). The resulting suspension was allowed to react for 5 hours at 20°C, 400 rpm. The particles were centrifuged (5 min at 1000 ref) and washed 3 times (by centrifugation during 5 min at 1000 ref) in phosphate buffer (20 mM, pH 8), PS80 (8 mg/L) and resuspended in phosphate buffer (20 mM, pH 8), PS80 (8 mg/L).
  • NP-3 was cured overnight in a water bath at 20°C.
  • An organosilica layer was grown at the surface of the immobilized BSA using APTES (7.7 mM), TEOS (40.4 mM) and benzyltriethoxysilane (35 mM). The resulting suspension was allowed to react for 5 hours at 20°C, 400 rpm. The particles were centrifuged (5 min at 1000 ref) and washed 3 times (by centrifugation during 5 min at 1000 ref) in phosphate buffer (20 mM, pH 8), PS80 (8 mg/L) and resuspended in phosphate buffer (20 mM, pH 8), PS80 (8 mg/L).
  • a solution of chitosan in acetic acid (0.1 M) was added to the particle suspension to achieve a final chitosan concentration of 121 pg/mL.
  • the reaction mixture was allowed to react for 30 min at 20°C, 400 rpm.
  • NP-4 was cured overnight in a water bath at 20°C.
  • Pancreatin (23.5 mg/mL) comprising lipase and/or a fragment thereof, protease and/or a fragment thereof and amylase and/or a fragment thereof was added, and the reaction mixture was allowed to react for 10 min at 20°C, 400 rpm.
  • An organosilica layer was grown at the surface of the immobilized lactase using APTES (7.2 mM) and TEOS (75.6 mM). The resulting suspension was allowed to react for 2 hours at 20°C, 400 rpm. The particles were washed 3 times (by centrifugation during 5 min at 20000 ref) in H2O/PS80 (8 mg/L) and resuspended in H2O/PS80 (8 mg/L).
  • chitosan in acetic acid 0.1 M was added to the particle suspension to achieve a final chitosan concentration of 103 pg/mL.
  • the reaction mixture was allowed to react for 30 min at 20°C, 400 rpm.
  • the particles were centrifuged 5 min at 20000 ref and washed 3 times in H2O/PS80 (8 mg/L).
  • NP-5 was cured overnight in a water bath at 20°C.
  • Particles were washed three times in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L) and resuspended in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L). Then, glutaraldehyde (3.1 mM) was added, and the reaction mixture was stirred for 10 min at 20°C, 400 rpm. Particles were washed three times in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L) and resuspended in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L).
  • a priming was performed by adding APTES (3.1 mM) and stirring the reaction mixture for 10 min at 20°C, 400 rpm. Particles were washed three times in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L) and resuspended in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L). Sodium taurocholate (2 mM) and pancreatin (15 g/L) were successively added and the reaction mixture was allowed to react for 10 min at 20°C, 400 rpm.
  • An organosilica layer was grown at the surface of the immobilized pancreatin using APTES (5.7 mM), TEOS (29.9 mM) and benzyltriethoxysilane (25.9 mM). The resulting suspension was allowed to react for 5 hours at 20°C, 400 rpm. Particles were washed three times in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L) and resuspended in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L). NP-3(1) were cured overnight in a water bath at 20°C.
  • pancreatin-based silica nanoparticles were produced in phosphate buffer (20 mM, pH 8), PS80 (8 mg/L) according to the section headed “Production ofNP-3” of “Example 3: Lipase, Amylase and Protease Immobilization and Protection” above.
  • the nanoparticles were not washed between each chemical step. Therefore, glutaraldehyde was still present during layer growth and caused a covalent binding of the protective layer to pancreatin.
  • the covalent binding of the protective layer to pancreatin can be observed by the appearance of a yellow/orange colour that has an absorbance maximum at 460 nm. This colour is due to the formation of an imine bond by reaction between the aldehyde functions of the glutaraldehyde linker and the primary amines of the amino acids of pancreatin and the organosilica layer.
  • the absorbance of pancreatin-based silica nanoparticles NP-3(1) and NP-3 at 460 nm was measured after the organosilica layer formation and final particles washing (see Figure 24), showing a much higher absorbance at 460 nm for NP-3 than for NP-3(1).
  • NP-3(1) still shows absorbance to some degree at this wavelength, as imine bonds are also formed during enzyme immobilization. However, the absorbance of NP-3 is significantly higher indicating an additional formation of imine bonds caused by covalent binding of the protective layer to pancreatin.
  • nanoparticles were labeled with a specific activity of 500-400 MBq/g nanoparticles according to the protocol stated below.
  • Nanoparticles were incubated with '"Lu (0.02M HC1) and ammonium acetate (IM, pH 5.4) for 12h at 45°C under continuous stirring. Nanoparticles were centrifuged at 5000g for 5min and resuspended in sodium acetate (20mM, pH 5) with polysorbate 80 (8mg/L). Then, the nanoparticles were resuspended in DTPA (ImM, pH 5) and incubated overnight at room temperature (RT) for quenching. The nanoparticles were then washed and resuspended in 0.9% sodium chloride with polysorbate 80 (8mg/L). Pancreatic lipase activity assay:
  • the olive oil solution was prepared by mixing olive oil / gum ararbic / water (1 / 8.25 / 0.75).
  • the buffer solution was prepared by dissolving Trizma base (0.6 g/L) and sodium chloride (2.34 g/L) in nanopure water.
  • the bile salts solution was prepared by dissolving sodium taurocholate (80 g/L) in water.
  • the activity assay was performed by mixing the olive oil solution (13.8 mL), the buffer solution (11 mL), the bile salts solution (2.8 mL) and water (12.4 mL) in a bioreactor at 37°C. The pH was adjusted to 9.2 by adding a sodium hydroxide solution (0.1 M). NP-3 (1.4 mL, 10 mg/mL) was washed twice in water and added to the bioreactor. Lipase kinetics was monitored by measuring the amount of sodium hydroxide added to the reaction mixture to maintain the pH at 9 for 10 minutes.
  • Pancreatin-based silica nanoparticles NP-3 amylase activity was assessed using the Sigma amylase assay kit.
  • the enzyme sample (2 pL, 18.2 mg/mL) was mixed with the activity buffer (48 pL).
  • the rats were fed with a pelleted complete diet “Altromin 1324” available ad libithum. They had access ad libitum to drinking water.
  • PDL Pancreatic duct ligation
  • duodenum catheterization Animals were anesthetized with isoflurane (2-4%) in an induction chamber before being moved to a nose cone with isoflurane for the surgery. With the rat in a supine position on a heated table the abdomen was opened in the midline. The pancreas was located and gently moved to locate the biliopancreatic duct. The pancreatic tissue around the biliopancreatic duct was bluntly dissected to visualize the pancreatic ducts.
  • pancreatin-based silica nanoparticles NP-3 efficacy were ligated close to the biliopancreatic duct to stop the flow of pancreatic enzymes.
  • a catheter C30PU-RDD1444, Instech Laboratories
  • the catheter was ligated to intestinal wall and subcutaneously tunneled to the neck of the animals where it was exteriorized. The abdomen and the incision in the neck were thereafter closed with sutures.
  • PDL rats were dosed through the duodenum with either inactive nanoparticles NP-4 (7mg) or pancreatin-based silica nanoparticles NP-3 (7mg; 7.5U) and 5 minutes later with triolein (lOmg) by oral gavage. Following dosing of triolein, approximatively 150 uL of blood was sampled in EDTA at 0.25, 0.5, 1, 1.5, 2, 4, and 6h.
  • Plasma samples were prepared according to the BUME method. Ten microliters of plasma sample were mixed with 300 pL of 1-butanol/methanol (3: 1, v/v). Samples were incubated for Ih at 20°C under stirring (900rpm). After centrifugation (16 000g, lOmin, 20°C), 50uL was transferred into glass vial and used for LC-MS.
  • the injection volume used was 2.5uL and the run time was 7.5 min at a flow rate of ImL/min.
  • Mobile phase A was 60% acetonitrile, 40% H2O, 5 mM NH4 acetate and mobile phase B was 90% isopropanol, 10% acetonitrile, 5 mM NH4 acetate.
  • Chromatographic separation was carried out using Waters Premier BEH C18 column (50mmx2.1mm) column (with the following gradient: from 15% B to 99% B).
  • the MS is performed by using the mass spectrometer Thermo Q Exactive with the acquisition mode DDA top5.
  • the MS parameters were the following: MSI resolution: 70'000 and MS2 resolution: 17'500.
  • the HCD fragmentation was performed with normalized stepped collision energy 10, 20 and 30.
  • the targeted extraction of EIC was TG 54:3 for triolein and the most abundant triglycerides. Data analysis was performed in Thermo quan Browser software.
  • the minipigs were fed with a pelleted complete diet “Altromin 9033” offered with a daily ration of approximatively 250g.
  • NP-3 efficacy chronic dosing
  • the diet was changed to high fat diet where the daily ration of Altromin 9033 was completed with olive oil (1 : 10 - olive oil: altromin) and 100g of apple sauce.
  • the high fat diet was initiated 15 days before the start of the dosing and maintained during the chronic administration of the treatment.
  • SPECT/CT scanning (Clinical D670 SPECT/CT, GE) were initiated 15 min, 3, 8, 24, 48 and 72 hours post dosing (+/- ’A h) of the In-111 -labeled nanoparticles.
  • no SPECT/CT scanning were initiated and 15 min, 3, 8, and 24 hours post dosing of the free In- 111.
  • the SPECT acquisition time was decided based on the count rate at the day of scanning.
  • SPECT imaging included two field of views (FOV) to cover the area ranging from the stomach to the rectum. The two FOVs were scanned with the FOV including the stomach and the duodenum as the first acquisition.
  • FOV field of views
  • an intravenous infusion of an iodine-containing contrast medium (Ultravist®, 370 mg/mL, 1 mL/kg, flow rate 2 ml/s) was performed to improve the visibility of the organs for image analysis.
  • FOV for CT imaging included the entire animal.
  • the animals were imaged on site and were transported from the holding room to the scanner under anesthesia.
  • a catheter Dog duodenal catheter 7F, SAI Infusion Technologies
  • the catheter was ligated to intestinal wall and subcutaneously tunneled to the back of the animals where it is exteriorized. The flank incision was thereafter sutured, and a protective bandage is applied around the abdomen.
  • Pre- and post-operative analgesia and antibiotics The animals were treated with preemptive analgesia in the form of intramuscular NS AID prior to surgery.
  • Post-operative analgesia consisted of oral NSAID once daily for 4 days, and additionally low-dose percutaneous opioid patches for 72 hours as need.
  • Antibiotics (amoxicillin) were administered intramuscularly prior to surgery and completed by oral administrations once daily for 4 days after surgery. o Evaluation of pancreatin-based silica nanoparticles NP-3 efficacy:
  • PDL minipigs were dosed through the intra duodenal catheter with either inactive nanoparticles NP-4 (1g) or pancreatin-based silica nanoparticles NP-3 (1g; 1365U) and sequentially with olive oil (14g) in the intra duodenal catheter. Following dosing of olive oil, 5mL of blood was sampled in EDTA at 0, 0.0833, 0.25, 0.5, 1, 2, 3, 4 and 6 hours.
  • Plasma samples were centrifuged (10 min, 4°C, 2000 x g), and a minimum of 500 uL plasma was transferred into Eppendorf tubes and stored at -80°C until analysis for triglycerides content.
  • PDL minipigs were dosed through the intra duodenal catheter with either inactive nanoparticles NP-4 (1g) or pancreatin-based silica nanoparticles NP-3 (1g; 1365U) on a daily basis twice a day before receiving their meal over a period of 10 days.
  • Caco2 human colorectal adenocarcinoma cell line
  • HT29-MTX-E12 human colon cancer cell line
  • DMEM fetal calf serum
  • 2mM L-glutamine 10% heat-inactivated fetal calf serum
  • 2mM L-glutamine 10% non-essential amino-acid
  • 100 U/mL penicillin/streptomycin 100 U/mL penicillin/streptomycin.
  • cells were seeded at a density of 2.6 x 10 5 cells/cm 2 in transwell PET inserts (1pm pore size). All cell models were used for experiments on day 21.
  • Caco-2 and HT-29-MTX-E12 cells were used at a ratio 75%-25%.
  • the integrity of the cell barrier was assessed by the measurement of the transepithelial electrical resistance (TEER) using the CellZscope system (NanoAnalytics). After cell culture medium refreshment and treatment with nanoparticles, automated measurements of the TEER for up to 24h every 15 minutes with a range from 1Hz to lOO’OOOHz.
  • TEER transepithelial electrical resistance
  • inactive DOTA-labelled silica nanoparticles non-functionalized (NP-2) and inactive DOTA-labelled silica nanoparticles functionalized with chitosan (NP-1) were administrated into the duodenum of minipigs by endoscopy.
  • SPECT/CT images were acquired and the biodistribution of the nanoparticles in the gastrointestinal tract was analysed using a 3- compartment analysis including small intestines, colon, and the rectal part of the colon.
  • the quantification of the NP-2 and NP-1 in the small intestine is shown on Figure 17A.
  • Example 2 Biocatalytic activities of pancreatin-based silica nanoparticles NP-3 and NP-5
  • Exocrine Pancreatic Insufficiency is a condition in which the exocrine functions of the pancreas are impaired and its ability to effectively deliver digestive enzymes to the duodenum is defective.
  • the standard medical therapy to treat clinical symptoms and malabsorption is oral pancreatic enzyme replacement therapy (PERT).
  • Current approved therapies consist in pancreatic enzyme product (lipase, amylase, protease) from porcine origin.
  • Pancreatin-based silica nanoparticles NP-3 and NP-5 have been assessed with regard to their enzymatic activities. Enzymatic activity of lipase and amylase of NP-3 is displayed in Figure 18A and Figure 18C. Enzymatic activity of protease of NP-5 is displayed in Figure 18B.
  • Example 3 In vivo activity of pancreatin-based silica nanoparticles NP-3 in PDL-rats Given the importance of fat digestion for patients with exocrine pancreatitis insufficiency (EPI), the validation of pancreatin-based silica nanoparticles NP-3 was assessed by focusing on its ability to digest lipids in vivo using PDL-rats as first animal model.
  • PDL-rats were dosed intraduodenally with pancreatin-based silica nanoparticles NP-3 or inactive nanoparticles NP-4 prior being gavaged with triolein (called hereafter dosing sequence). After a single dosing sequence, an increase of plasmatic TG was observed in PDL-rat that received NP-3 (active nanoparticles) compared to PDL-rat that received the inactive nanoparticles (NP-4) (Fig. 19). This result demonstrates the ability of pancreatin-based silica nanoparticles NP-3 to restore lipase digestive function in an EPI animal model.
  • Example 4 In vivo activity of pancreatin-based silica nanoparticles NP-3 in PDL-nunipigs From anatomical and physiological perspectives, the pig model is widely recognised to share high similarities with human gastrointestinal tract. So, PDL-minipigs have been generated to assess the efficacy of pancreatin-based silica nanoparticles NP-3. As previously described in PDL-rats model, the first validation of NP-3 consisted in a single dosing of the nanoparticles followed by the administration of olive oil in PDL-minipig.
  • pancreatin-based silica nanoparticles NP-3 When compared to a healthy minipigs, the increase of the plasmatic level of TG in PDL-minipig dosed with pancreatin-based silica nanoparticles NP-3 showed a similar kinetic with a maximal level at 3 hours after feeding (Fig. 20A).
  • the calculation of the area under the curve (AUC) demonstrates an extremely surprising digestion rate of 62% with pancreatin-based silica nanoparticles NP-3 compared with a healthy minipig (Fig. 20B).
  • Example 5 In vivo therapeutic efficacy of pancreatin-based silica nanoparticles NP-3 in PDL-nunipigs
  • pancreatin-based silica nanoparticles NP-3 To further point-out the ability of pancreatin-based silica nanoparticles NP-3 to restore lipase digestive functions, PDL-minipigs receiving a diet enriched with fat were daily dosed with pancreatin-based silica nanoparticles NP-3 over 10 days. As the primary end point of current treatments for EPI patient is the quantification of fat absorption, the benefits of pancreatinbased silica nanoparticles NP-3 were evaluated by measuring the unabsorbed fat excreted in feces.
  • Enzyme-replacement therapies to treat clinical symptoms and malabsorption are available.
  • a minimum dose of 40 000 - 50 000 Units of PERT-lipase is recommended at each main meals and half that dose with snacks.
  • Such doses lead to a heavy pill burden for the patients.
  • the treatment is not efficient and exhibits several limitations (persistence of the symptoms, low intraluminal survival time of the lipase, possible intolerance due to massive load of enzymes and gastrointestinal troubles due to massive amount of proteases).
  • Pancreatin-based silica nanoparticles NP-3 efficacy was compared to free pancreatin.
  • the amount of lipase activity administered with NP-3 was calculated based on the amount of fat ingestion (1 300U per dose for 14g of olive oil), while the amount of lipase activity administered with pancreatin followed the standard of care (40 000U per dose).
  • pancreatin-based silica nanoparticles NP-3 administered at a dose of 1300 U twice daily significantly improves digestive efficiency by 25% compared to pancreatin, the standard treatment, which was given at a much higher dose of 40000 U twice daily.
  • pancreatin at 80000 U per day facilitates 43.6% fat digestion, while NP-3 at 2600 U per day achieves 53.4% fat digestion (Fig. 2 IB).
  • Pancreatin-based silica nanoparticle NP-3 consists in a nanoparticle functionalized with mucoadhesive component allowing the interaction of the nanoparticles with the intestinal mucus (PCT/EP2023/051194). This results in a temporary engraftment of NP-3 and in a sustained lipase activity on the wall of the intestine. Additionally, the immobilization and protection of lipase on the nanoparticles protect the enzyme from external stresses (WO 2022/223699 Al) and stabilize its activity. So, this set of data demonstrate the added value of pancreatin-based silica nanoparticles NP-3 for lipase digestion and highlight the therapeutic potential of NP-3 for EPI patients.
  • Example 6 In vitro biocompatibility of pancreatin-based silica nanoparticles NP-5 Currently patients with exocrine pancreatic insufficiency take enormous amounts of pancreatin (10-20 pills/day), leading to a daily intake of high amount of proteases. Despite their digestive role, gastrointestinal proteases contribute to the intestinal homeostasis. Any imbalance in the level of proteases can lead to gastrointestinal pathologies (Vergnolle N et al., Gut 2016;65: 1215-1224).
  • pancreatin-based silica nanoparticles NP-5 we focused on the maintenance of the intestinal barrier integrity in presence of the nanoparticles and compared it to pancreatin (Fig. 22A).
  • the transepithelial electrical resistance (TEER) measurements across Caco2-HT29-MTX-E12 cell monolayers shows that the integrity of the intestinal epithelial barrier remains intact when in contact with NP-5 for 20h while the treatment with pancreatin leads to a dose-dependent loss of the barrier integrity.
  • TEER transepithelial electrical resistance
  • ZO-1 tight junction protein Zonula-Occludens-1
  • Example 7 Enhancing Pancreatin Stability through Covalent Attachment to the protective layer
  • pancreatin-based silica nanoparticles NP-3(1) were produced in buffered conditions and included washing after each chemical step (i.e. glutaraldehyde removal before layer growth).
  • pancreatin-based silica nanoparticles NP-3 were produced in non-buffered conditions without any intermediate washing steps (i.e. unreacted glutaraldehyde still present in the reaction mixture during layer growth).
  • Silica nanoparticles (50 nm) have been synthetized following the original Stober process as described in WO2015/014888 Al. Briefly, ethanol, distilled water (6 M) and ammonium hydroxide (0.13 M) were mixed and stirred at 400 rpm for 1 h. TEOS (0.28 M) was added and the solution was stirred at 400 rpm at 20°C for 22 h. The solution was then centrifuged at 20000 g for 20 min and washed successively with ethanol and water. Particle size measurement was carried out on SEM micrographs acquired at a magnification of 150000x using the image analysis software Olympus stream motion.
  • a recombinant human pancreatic lipase solution (525 pg/mL, 11 pM) was added and the reaction mixture was allowed to react for 10 min at 20 °C, 400 rpm.
  • An organosilica layer was grown at the surface of the immobilized lipase using APTES (4.2 mM), TEOS (21.8 mM) and benzyltriethoxysilane (18.9 mM).
  • the resulting suspension was allowed to react for 5 hours at 20 °C, 400 rpm.
  • the particles were centrifuged 5 min at 20000 ref and washed 3 times in H 2 O / PS80 (8 mg/L).
  • SNPs-HRL-ATB were cured overnight in a water bath at 20 °C.
  • HRL pancreatic lipase
  • CLPS colipase
  • An organosilica layer was grown at the surface of the immobilized proteins using APTES (4.2 mM), TEOS (21.8 mM) and benzyltri ethoxy silane (18.9 mM). The resulting suspension was allowed to react for 5 hours at 20 °C, 400 rpm. The particles were centrifuged 5 min at 20000 ref and washed 3 times in H 2 O / PS80 (8 mg/L). SNPs-HRL- CLPS-ATB were cured overnight in a water bath at 20 °C.
  • An organosilica layer was grown at the surface of the immobilized lipase using APTES (4.2 mM), TEOS (21.8 mM) and benzyltriethoxysilane (18.9 mM). The resulting suspension was allowed to react for 5 hours at 20 °C, 400 rpm. The particles were centrifuged 5 min at 20000 ref and washed 3 times in H 2 O / PS80 (8 mg/L). SNPs-PL-ATB were cured overnight in a water bath at 20 °C.
  • An organosilica layer was grown at the surface of the immobilized proteins using APTES (4.2 M), TEOS (21.8 mM) and benzyltri ethoxy silane (18.9 mM). The resulting suspension was allowed to react for 5 hours at 20 °C, 400 rpm. The particles were centrifuged 5 min at 20000 ref and washed 3 times in H 2 O / PS80 (8 mg/L). SNPs-PL-CLPS-ATB were cured overnight in a water bath at 20 °C.
  • porcine pancreatic lipase was co-immobilized with colipase, and protected in a hydrophobic organosilica shield on the surface of silica nanoparticles as described under B) above.
  • Activation of lipase by colipase was assessed using a fluorescent lipase substrate, l,2-Di-O-lauryl-rac-glycero-3 -(glutaric acid 6-methylresorufm ester) ( Figure 28).
  • An organosilica layer was grown at the surface of the immobilized lipase using APTES (4.2 mM), TEOS (21.8 mM) and benzyltriethoxysilane (18.9 mM). The resulting suspension was allowed to react for 5 hours at 20 °C, 400 rpm. The particles were centrifuged 5 min at 20000 ref and washed 3 times in H 2 O / PS80 (8 mg/L). SNPs-PL-NaTc-ATB were cured overnight in a water bath at 20 °C.
  • porcine pancreatic lipase was immobilized in presence of sodium taurocholate and protected in a hydrophobic organosilica shield on the surface of silica nanoparticles.
  • Activation of lipase by sodium taurocholate was assessed using a fluorescent lipase substrate, l,2-Di-O-lauryl-rac-glycero-3 -(glutaric acid 6-methylresorufm ester) ( Figure 30).
  • Example 4 Activation of pancreatic lipase (PL) with a colipase-mimicking peptide
  • PL pancreatic lipase
  • the peptide was chemically modified at its carboy end by adding a adding and-E-azido-Nle-OH group at its carboxy-end to enable cross-linking of the lipase enzyme at the surface of silica nanoparticles by click-chemistry.
  • HRL-based silica nanoparticles (NP-l(l)) were produced in H 2 O/PS80 (8 mg/L). Nanoparticles were washed after each chemical step resulting in glutaraldehyde removal. To SNPs (10 mg/mL, 69 nm) in H 2 O/PS80 (8 mg/L) was added APTES (3.1 mM). The reaction mixture was allowed to react for 10 min at 20°C, 400 rpm. Particles were washed three times in H 2 O/PS80 (8 mg/L) and resuspended in H 2 O/PS80 (8 mg/L).
  • Particles were washed three times in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L) and resuspended in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L). Then, glutaraldehyde (3.1 mM) was added, and the reaction mixture was stirred for 10 min at 20°C, 400 rpm. Particles were washed three times in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L) and resuspended in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L).
  • a priming was performed by adding APTES (3.1 mM) and stirring the reaction mixture for 10 min at 20°C, 400 rpm. Particles were washed three times in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L) and resuspended in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L). Sodium taurocholate (2 mM) and human recombinant lipase (0.732 g/L, 15.2 pM) were successively added and the reaction mixture was allowed to react for 10 min at 20°C, 400 rpm.
  • An organosilica layer was grown at the surface of the immobilized HRL using APTES (5.7 mM), TEOS (29.9 mM) and benzyltriethoxysilane (25.9 mM). The resulting suspension was allowed to react for 5 hours at 20°C, 400 rpm. Particles were washed three times in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L) and resuspended in phosphate buffer (25 mM, pH 7.5), PS80 (8 mg/L). NP-1(2) were cured overnight in a water bath at 20°C.
  • glutaraldehyde (3.1 mM) was added, and the reaction mixture was stirred for 10 min at 20°C, 400 rpm.
  • a priming was performed by adding APTES (3.1 mM) and stirring the reaction mixture for 10 min at 20°C, 400 rpm.
  • Sodium taurocholate (2 mM) and human recombinant lipase (0.732 g/L, 15.2 pM) were successively added and the reaction mixture was allowed to react for 10 min at 20°C, 400 rpm.
  • An organosilica layer was grown at the surface of the immobilized HRL using APTES (5.7 mM), TEOS (29.9 mM) and benzyltriethoxysilane (25.9 mM). The resulting suspension was allowed to react for 5 hours at 20°C, 400 rpm. Particles were washed three times in H 2 O/PS80 (8 mg/L) and resuspended in H 2 O/PS80 (8 mg/L). NP-1 were cured overnight in a water bath at 20°C.
  • the covalent binding of the protective layer to HRL can be observed by the appearance of a yellow/orange color that has an absorbance maximum at 460 nm. This color is due to the formation of an imine bond by reaction between the aldehyde functions of the glutaraldehyde linker and the primary amines of the amino acids of HRL and the organosilica layer.
  • the absorbance of HRL-based silica nanoparticles NP-l(l), NP-1(2), and NP-1 at 460 nm was measured after the organosilica layer formation and final particles washing (see Figure 33A). The results showed that NP-1 absorbed much more light than NP-1(2) at this wavelength.
  • NP-1 and NP-l(l) had similar absorbance values, even though NP-1 appeared darker visually. This suggests that the instrument could not distinguish the formation of imine bonds (due to the low enzyme amount used) because of the strong interference from the particles themselves.
  • HRL-based silica nanoparticles NP-1 (1) were produced in non-buffered conditions and included washing after each chemical step (i.e. glutaraldehyde removal before layer growth).
  • HRL-based silica nanoparticles NP-1 (2) were produced in buffered conditions and included washing after each chemical step (i.e. glutaraldehyde removal before layer growth).
  • HRL-based silica nanoparticles NP-1 were produced in non-buffered conditions without any intermediate washing steps (i.e. unreacted glutaraldehyde still present in the reaction mixture during layer growth).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un procédé de production d'une composition, la composition comprenant un support solide, une protéine ou un fragment de celle-ci immobilisé sur la surface du support solide, une couche de protection pour protéger la protéine ou le fragment de celle-ci par incorporation de la protéine ou du fragment de celle-ci, et un constituant fonctionnel immobilisé sur la surface de la couche de protection, le constituant fonctionnel immobilisé sur la surface de la couche de protection étant un polymère comprenant des unités de répétition, chaque unité de répétition comprenant au moins un groupe amino et/ou au moins un groupe thiol. La présente invention concerne également la composition pouvant être obtenue par le procédé.
PCT/EP2024/068917 2023-07-06 2024-07-04 Procédé d'immobilisation de protéines Pending WO2025008476A2 (fr)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP23183869.9 2023-07-06
EP23183881.4 2023-07-06
EP23183869 2023-07-06
EP23183875 2023-07-06
EP23183863.2 2023-07-06
EP23183881 2023-07-06
EP23183863 2023-07-06
EP23183875.6 2023-07-06

Publications (2)

Publication Number Publication Date
WO2025008476A2 true WO2025008476A2 (fr) 2025-01-09
WO2025008476A3 WO2025008476A3 (fr) 2025-02-20

Family

ID=91856292

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/068917 Pending WO2025008476A2 (fr) 2023-07-06 2024-07-04 Procédé d'immobilisation de protéines

Country Status (1)

Country Link
WO (1) WO2025008476A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015014888A1 (fr) 2013-07-30 2015-02-05 Inofea Gmbh Composition biocatalytique
WO2018148633A1 (fr) 2017-02-13 2018-08-16 Codexis, Inc. Polypeptides de phénylalanine ammonia-lyase modifiés
WO2022223699A1 (fr) 2021-04-22 2022-10-27 Perseo Pharma Ag Compositions biocatalytiques fonctionnalisées

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015014888A1 (fr) 2013-07-30 2015-02-05 Inofea Gmbh Composition biocatalytique
WO2018148633A1 (fr) 2017-02-13 2018-08-16 Codexis, Inc. Polypeptides de phénylalanine ammonia-lyase modifiés
WO2022223699A1 (fr) 2021-04-22 2022-10-27 Perseo Pharma Ag Compositions biocatalytiques fonctionnalisées

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Uniprot", Database accession no. P02703
BERNKOP-SCHNURCHTHALER, JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 89, no. 7, 2000, pages 901 - 9
KOLB ET AL., ANGEW. CHEM., vol. 40, no. 11, 2001, pages 2004 - 2021
MONTALTO ET AL., WORLD J GASTROENTEROL, vol. 12, no. 2, 14 January 2006 (2006-01-14), pages 187 - 91
VERGNOLLE N ET AL., GUT, vol. 65, 2016, pages 1215 - 1224
WITTIG G, A CHEM BER, vol. 94, 1961, pages 3260

Also Published As

Publication number Publication date
WO2025008476A3 (fr) 2025-02-20

Similar Documents

Publication Publication Date Title
Veider et al. Charge‐reversible nanoparticles: advanced delivery systems for therapy and diagnosis
Zhang et al. Investigation of lectin-modified insulin liposomes as carriers for oral administration
Lin et al. Multi-ion-crosslinked nanoparticles with pH-responsive characteristics for oral delivery of protein drugs
Song et al. Biogenic nanoselenium particles effectively attenuate oxidative stress-induced intestinal epithelial barrier injury by activating the Nrf2 antioxidant pathway
Zhang et al. Protein corona formed in the gastrointestinal tract and its impacts on oral delivery of nanoparticles
US10842747B2 (en) Nano-sized particles comprising multi-headed amphiphiles for targeted drug delivery
US20220133859A1 (en) Oral delivery of enzymes by nanocapsules for targeted metabolism of alcohol or toxic metabolites
Wang et al. Chitosan‐NAC nanoparticles as a vehicle for nasal absorption enhancement of insulin
Akkus et al. Zeta potential changing polyphosphate nanoparticles: a promising approach to overcome the mucus and epithelial barrier
US20250090643A1 (en) Functionalized biocatalytical compositions
Fuhrmann et al. Improving the stability and activity of oral therapeutic enzymes—Recent advances and perspectives
Song et al. Development of an M cell targeted nanocomposite system for effective oral protein delivery: preparation, in vitro and in vivo characterization
Su et al. Dynamic covalent bond‐assisted programmed and traceless protein release: high loading nanogel for systemic and cytosolic delivery
Datta et al. Enzyme therapy: a forerunner in catalyzing a healthy society?
Pang et al. Inhibition of furin by bone targeting superparamagnetic iron oxide nanoparticles alleviated breast cancer bone metastasis
CN108430514A (zh) 用于治疗过氧化物酶体病症和脑白质营养不良的组合物和方法
Filatova et al. Targeted delivery of anti-tuberculosis drugs to macrophages: targeting mannose receptors
US20060073210A1 (en) Nanoparticles for paracellular drug delivery
Santi et al. Protein delivery by peptide-based stealth liposomes: A biomolecular insight into enzyme replacement therapy
US20130004477A1 (en) Methods for Treating Inflammation and Oxidative Stress Related Diseases
WO2012162490A1 (fr) Compositions de nanozyme et procédés pour les synthétiser et les utiliser
US20080075731A1 (en) Materials and methods to reduce low density lipoprotein cholesterol
WO2025008476A2 (fr) Procédé d'immobilisation de protéines
Su et al. Multistage Continuous Targeting with Quantitatively Controlled Peptides on Chitosan‐Lipid Nanoparticles with Multicore–Shell Nanoarchitecture for Enhanced Orally Administrated Anticancer In Vitro and In Vivo
WO2025008458A1 (fr) Compositions biocatalytiques fonctionnalisées comprenant des enzymes pancréatiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24740116

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: AU2024289192

Country of ref document: AU